St. Jude Medical (STJ) 10-Q 6 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 28, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	28-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'ST JUDE MEDICAL INC	'
Entity Central Index Key	'0000203077	'
Current Fiscal Year End Date	'--12-28	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	291,813,213

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Earnings (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Net sales	$1,338	$1,326	$4,079	$4,131
Cost of sales:	'	'	'	'
Cost of sales before special charges	383	348	1,123	1,073
Special charges	2	7	21	46
Total cost of sales	385	355	1,144	1,119
Gross Profit	953	971	2,935	3,012
Selling, general and administrative expense	452	456	1,409	1,440
Research and development expense	172	170	505	518
Special charges	16	110	118	179
Operating profit	313	235	903	875
Other expense, net	17	19	248	67
Earnings before noncontrolling interest and income taxes	296	216	655	808
Income tax expense (benefit)	44	40	74	176
Net earnings before noncontrolling interest	252	176	581	632
Net loss attributable to noncontrolling interest	-10	0	-19	0
Net earnings attributable to St. Jude Medical, Inc.	$262	$176	$600	$632
Net earnings per share attributable to St. Jude Medical, Inc.:	'	'	'	'
Basic	$0.91	$0.56	$2.10	$2.01
Diluted	$0.90	$0.56	$2.08	$2
Cash dividends declared per share:	$0.25	$0.23	$0.75	$0.69
Weighted average shares outstanding:	'	'	'	'
Basic	287.5	314.7	285.6	314.8
Diluted	292	316.3	288.7	316.4

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Net earnings before noncontrolling interest	$252	$176	$581	$632
Other comprehensive income (loss), net of tax:	'	'	'	'
Unrealized gain on available-for-sale securities	0	4	1	10
Unrealized gain on derivative financial instruments	0	0	3	0
Reclassification of realized gain to net earnings on available-for-sale securities	-2	-3	-5	-8
Foreign currency translation adjustment	51	44	10	-2
Other comprehensive income (loss)	49	45	9	0
Total comprehensive income before noncontrolling interest	301	221	590	632
Total comprehensive loss attributable to noncontrolling interest	-10	0	-19	0
Total comprehensive income attributable to St. Jude Medical, Inc.	$311	$221	$609	$632

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$1,245	$1,194
Accounts receivable, less allowance for doubtful accounts of $46 million and $47 million at September 28, 2013 and December 29, 2012, respectively	1,399	1,349
Inventories	687	610
Deferred income taxes, net	211	220
Other current assets	203	178
Total current assets	3,745	3,551
Property, plant and equipment, at cost	2,776	2,629
Less accumulated depreciation	-1,349	-1,204
Net property, plant and equipment	1,427	1,425
Goodwill	3,383	2,961
Intangible assets, net	898	804
Other assets	512	530
TOTAL ASSETS	9,965	9,271
Liabilities and Shareholders' Equity	'	'
Current debt obligations	66	530
Accounts payable	182	254
Dividends payable	72	68
Income taxes payable	0	142
Employee compensation and related benefits	285	299
Other current liabilities	437	482
Total current liabilities	1,042	1,775
Long-term debt	3,403	2,550
Deferred income taxes, net	357	323
Other liabilities	717	529
Total liabilities	5,519	5,177
Commitments and Contingencies (Note 6)	0	0
Shareholders' Equity	'	'
Preferred stock ($1.00 par value; 25,000,000 shares authorized; none outstanding)	0	0
Common stock ($0.10 par value; 500,000,000 shares authorized; 288,968,747 and 295,648,327 shares issued and outstanding at September 28, 2013 and December 29, 2012, respectively)	29	30
Additional paid-in capital	292	0
Retained earnings	3,885	4,018
Accumulated other comprehensive income	55	46
Total shareholders' equity before noncontrolling interest	4,261	4,094
Noncontrolling interest	185	0
Total shareholders' equity	4,446	4,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$9,965	$9,271

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable allowance for doubtful accounts	$46	$47
Preferred stock, par value	$1	$1
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	288,968,747	295,648,327
Common stock, shares outstanding	288,968,747	295,648,327

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
OPERATING ACTIVITIES	'	'
Net earnings before noncontrolling interest	$581	$632
Adjustments to reconcile net earnings to net cash from operating activities:	'	'
Depreciation and amortization	220	212
Amortization of debt premium	-4	-8
Share-based compensation	50	54
Gain on sale of investment	-9	-14
Loss on retirement of long-term debt	161	0
Deferred income taxes	-1	-34
Other, net	37	73
Changes in operating assets and liabilities, net of business acquisitions:	'	'
Accounts receivable	-70	13
Inventories	-77	-26
Other current assets	31	29
Accounts payable and accrued expenses	-94	-16
Income taxes payable	-154	24
Net cash provided by operating activities	671	939
INVESTING ACTIVITIES	'	'
Purchases of property, plant and equipment	-171	-188
Payments to Acquire Businesses, Net of Cash Acquired	-171	0
Proceeds from sale of investments	10	19
Other investing activities, net	-15	-28
Net cash used in investing activities	-347	-197
FINANCING ACTIVITIES	'	'
Exercise of stock options and stock issued, including excess tax benefits	275	107
Common stock repurchased, including related costs	-609	-300
Dividends paid	-210	-212
Issuances (payments) of commercial paper borrowings, net	-8	-272
Borrowings under debt facilities	2,092	0
Payments under debt facilities	-1,659	0
Other financing activities, net	-151	0
Net cash used in financing activities	-270	-677
Effect of currency exchange rate changes on cash and cash equivalents	-3	0
Net increase in cash and cash equivalents	51	65
Cash and cash equivalents at beginning of period	1,194	986
Cash and cash equivalents at end of period	1,245	1,051
Noncontrolling interest	$204	$0

Basis_Of_Presentation

Basis Of Presentation	9 Months Ended
	Sep. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis Of Presentation	'
	BASIS OF PRESENTATION
	Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements of St. Jude Medical, Inc. (St. Jude Medical or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (U.S. generally accepted accounting principles) for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of the Company’s consolidated results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and footnotes. Actual results could differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended December 29, 2012 (2012 Annual Report on Form 10-K).
	The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and entities for which St. Jude Medical has a controlling financial interest. Intercompany transactions and balances have been eliminated in consolidation. For variable interest entities (VIEs), the Company assesses the terms of its interest in the entity to determine if St. Jude Medical is the primary beneficiary. Variable interests are ownership, contractual or other interests in an entity that change with increases or decreases in the fair value of the VIE's net assets exclusive of variable interests. The entity that consolidates the VIE is considered the primary beneficiary, and is defined as the party with (1) the power to direct activities of the VIE that most significantly affect the VIE's economic performance and (2) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE. In the first quarter of 2013, the Company determined that CardioMEMS, Inc. (CardioMEMS) was a VIE for which the Company is the primary beneficiary and began consolidating their results effective February 27, 2013. Additionally, during the second quarter of 2013, the Company entered into a $40 million equity investment, contingent acquisition agreement and exclusive distribution agreement with Spinal Modulation, Inc. (Spinal Modulation) and determined it also was a VIE for which the Company is the primary beneficiary. The Company began consolidating Spinal Modulation's results effective June 7, 2013 (see Note 2).
	On August 30, 2012, the Company announced the realignment of its product divisions into two new business units (or divisions): the Implantable Electronic Systems Division (IESD) (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (CATD) (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes were part of a comprehensive plan to accelerate the Company's growth, reduce costs, leverage economies of scale and increase its investment in product development. The Company began reporting under the new organizational structure as of the beginning of fiscal year 2013. As a result, certain prior period amounts have been recast to conform to the Company's new organizational structure in this Quarterly Report on Form 10-Q. See Note 14 for further information on the Company's segments.
	New Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02), an update to Comprehensive Income (Topic 220). ASU 2013-02 requires an entity to present either on the face of the statement where net income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items in the statement presenting net income. Additionally, disclosures about the changes in each component of accumulated other comprehensive income are also required. ASU 2013-02 requires prospective application and is effective for all fiscal years and interim periods beginning after December 15, 2012. The Company adopted ASU 2013-02 in the first quarter of 2013 and there was no impact to the Company's financial statements. Refer to Note 9 for the Company's disclosures required by ASU 2013-02.

Business_Combinations_Business

Business Combinations Business Combinations	9 Months Ended
	Sep. 28, 2013
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	BUSINESS COMBINATIONS
	Endosense S.A.: On August 19, 2013, the Company acquired all the outstanding shares of Endosense S.A. (Endosense) for the equivalent of $171 million (160 million Swiss Francs) in net cash consideration using available cash from outside the U.S. Endosense is based in Geneva, Switzerland and develops, manufactures and markets the TactiCath® irrigated ablation catheter to provide physicians a real-time, objective measure of the force to apply to the heart wall during a catheter ablation procedure. The Endosense force-sensing technology is CE Mark approved for atrial fibrillation and supra ventricular tachycarida ablation. Under the terms of the agreement, the transaction also provides for an additional cash payment of up to 150 million Swiss Francs (approximately $165 million at September 28, 2013), contingent upon both the achievement and timing of U.S. Food and Drug Administration (FDA) approval.
	Consistent with the provisions of Accounting Standards Codification (ASC) Topic 805, Business Combinations (ASC Topic 805), the Company accrued the contingent payment after determining its fair value of $132 million in arriving at $303 million of total consideration, net of cash acquired. The contingent consideration accrual will be remeasured to fair value at each reporting period with changes in fair value reflected in the statement of earnings.
	The preliminary allocation of the Endosense purchase price to the estimated fair values of net assets acquired was as follows (in millions):
		19-Aug-13
	Assets acquired:
	Current assets	$	2
	Goodwill	258
	Acquired in-process research and development (IPR&D)	33
	Other intangible assets	20
	Other long-term assets	1
	Total assets acquired	314
	Liabilities assumed:
	Current liabilities	11
	Net assets acquired	303
	Cash paid	180
	Cash acquired	(9		)
	Net cash consideration	171
	Contingent consideration	132
	Total purchase consideration	$	303
	The goodwill recorded as a result of the Endosense acquisition is not deductible for income tax purposes and was entirely allocated to the CATD reportable segment. The goodwill represents the strategic benefits of growing the Company's atrial fibrillation product portfolio and the expected revenue growth from increased market penetration from future products and customers. The Company now has the potential to integrate the force-sensing technology to offer a MediGuide™-enabled force-sensing ablation catheter and incorporate force sensing data into its EnSite Velocity™ Mapping System. In connection with the acquisition of Endosense, the Company recognized $20 million of developed technology intangible assets that have an estimated useful life of 7 years and $33 million of acquired in-process research and development (IPR&D) that was capitalized as an indefinite-lived intangible asset. Upon completion of the related development projects (when U.S. regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life.
	The results of Endosense since the date of acquisition and pro forma disclosures of the consolidated results of the Company with the full year effects of Endosense have not been separately presented since the impact to the Company's results of operations was not material.
	Spinal Modulation, Inc.: On June 7, 2013, the Company made an equity investment of $40 million in Spinal Modulation, a privately-held company that is focused on the development of an intraspinal neuromodulation therapy that delivers spinal cord stimulation targeting the dorsal root ganglion to manage chronic pain. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire Spinal Modulation for payments of up to $300 million during the period that extends through the completion of certain regulatory milestones. If the Company acquires Spinal Modulation, the contingent acquisition agreement also provides for additional consideration payments contingent upon the achievement of certain revenue-based milestones. In the event the Company acquires the noncontrolling interest of Spinal Modulation, the contingent payments would be recognized at the then-current fair value as an equity transaction. Additionally, in connection with the investment and contingent acquisition agreement, the Company also entered into an exclusive international distribution agreement, and obtained significant decision-making rights over Spinal Modulation's operations and economic performance. The Company also committed to providing additional debt financing to Spinal Modulation up to $15 million. Accordingly, effective June 7, 2013, the Company determined that Spinal Modulation was a VIE for which St. Jude Medical is the primary beneficiary. Therefore, as of June 7, 2013, the financial condition and results of operations of Spinal Modulation were included in St. Jude Medical's consolidated financial statements. The Company has a 19% voting equity interest in Spinal Modulation and allocates the losses attributable to Spinal Modulation's noncontrolling shareholders to noncontrolling interest in St. Jude Medical's statements of earnings and consolidated balance sheets. The results of Spinal Modulation since the date of its initial consolidation and pro forma disclosures of the consolidated results of the Company with the full year effects of Spinal Modulation have not been separately presented since the impact to the Company's results of operations was not material.
	The initial consolidation of a VIE that is determined to be a business is accounted for as a business combination. The following table summarizes the estimated fair values of Spinal Modulation’s assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the June 7, 2013 consolidation date, and as of September 28, 2013 after elimination of all intercompany balances and transactions (in millions):
		7-Jun-13			28-Sep-13
	Cash and cash equivalents	$	41		$	31
	Other current assets	9			6
	Goodwill	82			82
	Acquired in-process research and development (IPR&D)	45			45
	Other intangible assets	7			7
	Other long-term assets	1			1
	Total assets	185			172
	Current liabilities	6			5
	Deferred income taxes, net	19			19
	Total liabilities	25			24
	Non-controlling interest	$	120		$	111
	The initial allocation of Spinal Modulation’s assets and liabilities included in the Company’s consolidated balance sheet was based upon preliminary valuations, and the estimated fair values of assets and liabilities were subject to change as the valuations were finalized within the initial measurement period. In the three-month period ended September 28, 2013, the Company finalized the valuations and allocation of the estimated fair values of Spinal Modulation’s assets and liabilities and recorded a $35 million decrease to goodwill, a $5 million decrease to acquired IPR&D, a $3 million decrease to purchased technology intangible assets, a $3 million decrease to liabilities and a $40 million reduction to noncontrolling interest. These changes have been reflected retrospectively in the June 7, 2013 balances presented in the previous table.
	The cash and cash equivalents balance of Spinal Modulation at June 7, 2013 includes $40 million of the Company’s equity investment proceeds. Assets recorded as a result of consolidating Spinal Modulation into the Company's consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. The creditors of Spinal Modulation do not have any recourse to the general credit of St. Jude Medical.
	The goodwill recognized in connection with the Spinal Modulation transaction was not deductible for income tax purposes and was allocated entirely to the Company's IESD segment. The goodwill represents the strategic benefits of growing the Company's neuromodulation chronic pain portfolio as well as the expected revenue growth from increased market penetration. The Company recognized $45 million of indefinite-lived IPR&D intangible assets. Upon completion of the related development project (generally when regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life. The Company also recognized $7 million of purchased technology intangible assets with an estimated useful life of 12 years.
	CardioMEMS, Inc.: During 2010, the Company made an equity investment of $60 million in CardioMEMS, a privately-held company that is focused on the development of a wireless monitoring technology that can be placed directly into the pulmonary artery to assess cardiac performance via measurement of pulmonary artery pressure. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire CardioMEMS for an additional payment of $375 million less any net debt payable to St. Jude Medical, Inc. during the period that extends through the completion of certain regulatory milestones.
	In the first quarter of 2013, the Company obtained significant decision-making rights over CardioMEMS' operations and provided debt financing of $28 million to CardioMEMS which was collateralized by substantially all the assets of CardioMEMS including its intellectual property. In July 2013, the Company provided $9 million of additional debt financing to CardioMEMS. In accordance with ASC Topic 810, Consolidations (ASC Topic 810), the Company reconsidered and determined that effective February 27, 2013 CardioMEMS was a VIE for which St. Jude Medical is the primary beneficiary. As a result, as of February 27, 2013, the financial condition and results of operations of CardioMEMS were included in St. Jude Medical's consolidated financial statements. The Company recognized a $29 million charge to other expense (see Note 10) to adjust the carrying value of the pre-existing equity investment and fixed price purchase option to fair value. The Company continues to hold a 19% voting equity interest in CardioMEMS and allocates the losses attributable to CardioMEMS' noncontrolling shareholders to noncontrolling interest in St. Jude Medical's consolidated statements of earnings and consolidated balance sheets. The results of CardioMEMS since the date of acquisition and pro forma disclosures of the consolidated results of the Company with the full year effects of CardioMEMS have not been separately presented since the impact to the Company's results of operations was not material.
	The initial consolidation of a VIE that is determined to be a business is accounted for as a business combination. The following table summarizes the estimated fair values of CardioMEMS’ assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the February 27, 2013 consolidation date, and as of September 28, 2013 after elimination of all intercompany balances and transactions (in millions):
		27-Feb-13			28-Sep-13
	Cash and cash equivalents	$	33		$	21
	Other current assets	2			4
	Goodwill	83			83
	Acquired in-process research and development (IPR&D)	63			63
	Other long-term assets	2			2
	Total assets	183			173
	Current liabilities	13			6
	Deferred income taxes, net	23			23
	Other liabilities	5			4
	Total liabilities	41			33
	Non-controlling interest	$	84		$	74
	The initial allocation of CardioMEMS’ assets and liabilities included in the Company’s consolidated balance sheet was based upon preliminary valuations, and the estimated fair values of assets and liabilities were subject to change as the valuations were finalized within the initial measurement period. In the three-month period ended September 28, 2013, the Company finalized the valuations and allocation of the estimated fair values of CardioMEMS’ assets and liabilities and recorded a $1 million decrease to goodwill, a $6 million decrease to acquired IPR&D, a $2 million decrease to liabilities and a $5 million reduction to noncontrolling interest. These changes have been reflected retrospectively in the February 27, 2013 balances presented in the previous table.
	The cash and cash equivalents balance of CardioMEMS at February 27, 2013 includes $28 million of the Company’s debt financing proceeds. Assets recorded as a result of consolidating CardioMEMS into the Company's consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. The other creditors of CardioMEMS do not have any recourse to the general credit of St. Jude Medical.
	The goodwill recognized in connection with the CardioMEMS transaction was not deductible for income tax purposes and was allocated entirely to the Company's IESD segment. The goodwill represents the strategic benefits of growing the Company's cardiac rhythm management and heart failure therapy product portfolio as well as the expected revenue growth from increased market penetration. The Company recognized $63 million of indefinite-lived IPR&D intangible assets. Upon completion of the related development projects (generally when regulatory approval to market the product is obtained), the IPR&D will be amortized over its estimated useful life.
	Nanostim, Inc.: As of September 28, 2013, the Company held an investment in Nanostim, Inc. (Nanostim), which provided the Company with an 18% voting equity interest. Nanostim is a development stage company, based in Sunnyvale, California that has developed a miniaturized and the first leadless cardiac pacemaker system, which received CE mark approval in August 2013. The Nanostim™ leadless pacemaker also received FDA conditional approval for its Investigation Device Exemption application and pivotal clinical trial protocol to begin evaluating the technology in the U.S. The terms of the Company’s original investment agreement with Nanostim included an exclusive fixed price purchase option to acquire the remaining 82% interest in Nanostim. The Company previously concluded that Nanostim was a VIE, but that St. Jude Medical was not the primary beneficiary of Nanostim as it did not retain power to direct the activities of Nanostim that most significantly impacted its economic performance. The Company has reflected its investment in Nanostim as a cost method investment in other assets.
	On October 11, 2013, the Company exercised it exclusive purchase option and acquired all the outstanding shares of Nanostim for $118 million in net cash consideration. The Company's 18% voting equity interest in Nanostim will be remeasured to fair value as part of the Company's acquisition accounting. Under the terms of the agreement, the transaction also provides for additional cash payments of up to $65 million, contingent upon the achievement and timing of certain revenue-based milestones. As of the date of these financial statements, the Company had not fully completed its valuation of the net assets acquired from Nanostim and is unable to reasonably disclose the effects this business combination will have on the Company’s consolidated balance sheet. A preliminary valuation of the Company’s pre-existing equity interest and an allocation of the total purchase consideration to the estimated fair values of net assets acquired is expected to be completed in the fourth quarter of 2013.

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets	9 Months Ended
	Sep. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill And Other Intangible Assets	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	The changes in the carrying amount of goodwill for each of the Company’s reportable segments (see Note 14) for the nine months ended September 28, 2013 were as follows (in millions):
		IESD			CATD		Total
	Balance at December 29, 2012	$	1,229		$	1,732	$	2,961
	Endosense S.A.	—			258		258
	Spinal Modulation, Inc.	82			—		82
	CardioMEMS, Inc.	83			—		83
	Foreign currency translation and other	(12		)	11		(1		)
	Balance at September 28, 2013	$	1,382		$	2,001	$	3,383
	The following table provides the gross carrying amount of other intangible assets and related accumulated amortization (in millions):
		September 28, 2013					December 29, 2012
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Definite-lived intangible assets:
	Purchased technology and patents	$	954		$	374	$	947		$	336
	Customer lists and relationships	22			16		57			36
	Trademarks and tradenames	22			11		22			10
	Licenses, distribution agreements and other	4			2		6			4
		$	1,002		$	403	$	1,032		$	386
	Indefinite-lived intangible assets:
	Acquired IPR&D	$	250				$	109
	Trademarks and tradenames	49					49
		$	299				$	158
	During the second quarter of 2013, the Company recognized a $13 million impairment charge primarily associated with customer relationship intangible assets (see Note 7). The gross carrying amounts and related accumulated amortization amounts for these impairment charges were written off accordingly.

Inventories

Inventories	9 Months Ended
	Sep. 28, 2013
Inventory, Net [Abstract]	'
Inventory Disclosure	'
	INVENTORIES
	The Company’s inventories consisted of the following (in millions):
		September 28, 2013		December 29, 2012
	Finished goods	$	475	$	416
	Work in process	59		50
	Raw materials	153		144
		$	687	$	610

Debt

Debt	9 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	The Company’s debt consisted of the following (in millions):
		September 28, 2013		December 29, 2012
	2.20% senior notes due 2013 (retired September 2013)	$	—	$	454
	3.75% senior notes due 2014 (redeemed May 2013)	—		699
	2.50% senior notes due 2016	513		518
	4.875% senior notes due 2019 (redeemed May 2013)	—		496
	3.25% senior notes due 2023	896		—
	4.75% senior notes due 2043	696		—
	Term loan due 2015	500		—
	1.58% Yen-denominated senior notes due 2017	83		95
	2.04% Yen-denominated senior notes due 2020	130		149
	Yen-denominated credit facilities	66		76
	Commercial paper borrowings	585		593
	Total debt	3,469		3,080
	Less: current debt obligations	66		530
	Long-term debt	$	3,403	$	2,550
	Expected future minimum principal payments under the Company’s debt obligations as of September 28, 2013 are as follows: $66 million in 2014; $500 million in 2015; $500 million in 2016; $83 million in 2017; and $2,315 million in years thereafter.
	Senior Notes Due 2013: In March 2010, the Company issued $450 million principal amount of 3-year, 2.20% unsecured senior notes (2013 Senior Notes) that matured on September 15, 2013, which the Company paid in full utilizing commercial paper borrowings and cash generated from operations.
	Senior Notes Due 2016: In December 2010, the Company issued $500 million principal amount of 5-year, 2.50% unsecured senior notes (2016 Senior Notes) that mature in January 2016. The majority of the net proceeds from the issuance of the 2016 Senior Notes was used for general corporate purposes including the repurchase of the Company’s common stock. Interest payments are required on a semi-annual basis. The 2016 Senior Notes were issued at a discount, yielding an effective interest rate of 2.54% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2016 Senior Notes at any time at the applicable redemption price.
	Concurrent with the issuance of the 2016 Senior Notes, the Company entered into a 5-year, $500 million notional amount interest rate swap designated as a fair value hedge of the changes in fair value of the Company’s fixed-rate 2016 Senior Notes. In June 2012, the Company terminated the interest rate swap and received a cash payment of $24 million. The gain from terminating the interest rate swap agreement has been reflected as an increase to the carrying value of the debt and is being amortized as a reduction of interest expense resulting in a net average interest rate of 1.3% that will be recognized over the remaining term of the 2016 Senior Notes.
	Senior Notes Due 2023: In April 2013, the Company issued $900 million principal amount of 10-year, 3.25% unsecured senior notes (2023 Senior Notes) that mature in April 2023. Interest payments are required on a semi-annual basis. The 2023 Senior Notes were issued at a discount, yielding an effective interest rate of 3.31% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2023 Senior Notes at any time at the applicable redemption price.
	Senior Notes Due 2043: In April 2013, the Company issued $700 million principal amount of 30-year, 4.75% unsecured senior notes (2043 Senior Notes) that mature in April 2043. Interest payments are required on a semi-annual basis. The 2043 Senior Notes were issued at a discount, yielding an effective interest rate of 4.79% at issuance. The debt discount is being amortized as interest expense through maturity. The Company may redeem the 2043 Senior Notes at any time at the applicable redemption price.
	In May 2013, the Company used the majority of the proceeds from the issuance of its 2023 Senior Notes and 2043 Senior Notes to redeem both $700 million principal amount of 5-year, 3.75% unsecured senior notes originally due in 2014 (2014 Senior Notes) and $500 million principal amount of 10-year, 4.875% unsecured senior notes originally due in 2019 (2019 Senior Notes). In connection with the redemption of these senior notes, the Company recognized an aggregate $161 million charge in the second quarter of 2013 primarily associated with required make-whole redemption payments to noteholders from the senior notes being retired prior to their scheduled maturity.
	Term Loan Due 2015: In June 2013, the Company entered into a 2-year, $500 million unsecured term loan, the proceeds of which were used for general corporate purposes including the repayment of outstanding commercial paper borrowings of the Company. These borrowings bear interest at LIBOR plus 0.5%, subject to adjustment in the event of a change in the Company's credit ratings. The Company may make principal payments on the outstanding borrowings any time after June 26, 2014.
	1.58% Yen-Denominated Senior Notes Due 2017: In April 2010, the Company issued 7-year, 1.58% unsecured senior notes in Japan (1.58% Yen Notes) totaling 8.1 billion Japanese Yen (the equivalent of $83 million at September 28, 2013 and $95 million at December 29, 2012). The principal amount of the 1.58% Yen Notes recorded on the balance sheet fluctuates based on the effects of foreign currency translation. Interest payments are required on a semi-annual basis and the entire principal balance is due on April 28, 2017.
	2.04% Yen-Denominated Senior Notes Due 2020: In April 2010, the Company issued 10-year, 2.04% unsecured senior notes in Japan (2.04% Yen Notes) totaling 12.8 billion Japanese Yen (the equivalent of $130 million at September 28, 2013 and $149 million at December 29, 2012). The principal amount of the 2.04% Yen Notes recorded on the balance sheet fluctuates based on the effects of foreign currency translation. Interest payments are required on a semi-annual basis and the entire principal balance is due on April 28, 2020.
	Yen–Denominated Credit Facilities: In March 2011, the Company borrowed 6.5 billion Japanese Yen (the equivalent of $66 million at September 28, 2013 and $76 million at December 29, 2012) under uncommitted credit facilities with two commercial Japanese banks that provide for borrowings up to a maximum of 11.25 billion Japanese Yen. The principal amount reflected on the balance sheet fluctuates based on the effects of foreign currency translation. Half of the borrowings bear interest at Yen LIBOR plus 0.25% and mature in March 2014 and the other half of the borrowings bear interest at Yen LIBOR plus 0.275% and mature in June 2014. The maturity dates of each credit facility automatically extend for a one-year period, unless the Company elects to terminate the credit facility.
	Other Available Borrowings: In May 2013, the Company entered into a $1.5 billion unsecured committed credit facility (Credit Facility) that it may draw on for general corporate purposes and to support its commercial paper program. The Credit Facility expires in May 2018. Borrowings under the Credit Facility bear interest initially at LIBOR plus 0.8%, subject to adjustment in the event of a change in the Company’s credit ratings. The Credit Facility replaces the Company's previous $1.5 billion credit facility that was scheduled to expire in February 2015. As of September 28, 2013 and December 29, 2012, the Company had no outstanding borrowings under either credit facility.
	The Company’s commercial paper program provides for the issuance of unsecured commercial paper with maturities up to 270 days. As of September 28, 2013 and December 29, 2012, the Company's commercial paper borrowings were $585 million and $593 million, respectively. During the first nine months of 2013, the Company’s weighted average effective interest rate on its commercial paper borrowings was approximately 0.24%. Any future commercial paper borrowings would bear interest at the applicable then-current market rates. The Company classifies all of its commercial paper borrowings as long-term debt, as the Company has the ability and intent to repay any short-term maturity with available cash from its existing long-term, committed Credit Facility.

Commitments_And_Contingencies

Commitments And Contingencies

9 Months Ended

Sep. 28, 2013

Commitments and Contingencies Disclosure [Abstract]

'

Commitments And Contingencies

'

COMMITMENTS AND CONTINGENCIES

Product Liability Litigation

Riata® Litigation: In April 2013, a lawsuit seeking a class action was filed against the Company in the U.S. District Court for the Western District of Washington by plaintiffs alleging they suffered injuries caused by Riata® and Riata® ST Silicone Defibrillation Leads. The potential class of plaintiffs in this lawsuit is limited to residents of the State of Washington. The complaint seeks compensatory damages in unspecified amounts, punitive damages and a declaratory judgment that the Company is liable to the proposed class members for any past, present and future evaluative monitoring, and corrective medical, surgical and incidental expenses and losses.

As of November 1, 2013, the Company is aware of 35 lawsuits from plaintiffs alleging injuries caused by, and asserting product liability claims concerning, Riata® and Riata® ST Silicone Defibrillation Leads. Most of the lawsuits have been brought by a single plaintiff, but some of them name multiple individuals as plaintiffs. The action in Washington is the only case that seeks a class action. Outside of this class action, five separate multi-plaintiff lawsuits have been initiated against the Company that involve more than one unrelated plaintiff: a multi-plaintiff lawsuit joining 29 unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 4, 2013; a multi-plaintiff lawsuit joining two unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 4, 2013; a multi-plaintiff lawsuit joining two claimants was filed in the United States District Court for the Central District of California on April 4, 2013; a multi-plaintiff lawsuit joining three unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on April 29, 2013; and a multi-plaintiff lawsuit joining 21 unrelated claimants was filed in the Superior Court of California for the city and county of Los Angeles on July 15, 2013. Of the 35 lawsuits, fourteen cases are pending in federal courts, including three in the U.S. District Court for the District of Minnesota, five in the U.S. District Court for the Central District of California, one in the U.S. District Court for the District of South Carolina, one in the U.S. District Court for the Northern District of Georgia, one in the U.S. District Court for the Northern District of New York, one in the U.S. District Court for the Western District of New York, one in the U.S. District Court for the Middle District of Tennessee and one discussed above pending in the U.S. District Court for the Western District of Washington. The remaining 21 lawsuits are pending in state courts across the country, including seven in Minnesota, ten in California, one in Indiana, two in Kentucky and one in Florida.

All but one of the claimants in the aforementioned suits allege bodily injuries as a result of surgical removal and replacement of Riata® leads, or other complications, which they attribute to the leads. The majority of the claimants who seek recovery for implantation and/or surgical removal of Riata® leads are seeking compensatory damages in unspecified amounts, and declaratory judgments that the Company is liable to the claimants for any past, present and future evaluative monitoring, and corrective medical, surgical and incidental expenses and losses. Several claimants also seek punitive damages. The Company is responsible for legal costs incurred in defense of the Riata product liability claims including any potential settlements, judgments and other legal defense costs.

Silzone® Litigation and Insurance Receivables: The Company has been sued in various jurisdictions beginning in March 2000 by some patients who received a heart valve product with Silzone® coating, which the Company stopped selling in January 2000. The Company's outstanding Silzone cases consist of one class action in Ontario that has been appealed by the plaintiffs and one individual case in Ontario. In June 2012, the Ontario Court ruled in the Company's favor on all nine common class issues in a class action involving Silzone patients, and the case was dismissed. In September 2012, counsel for the class filed an appeal with the Court of Appeal for the Province of Ontario and filed their initial appellate brief in February 2013. The Company filed its responsive brief in August 2013. The oral argument concerning the appeal was expected to be heard in November 2013 but that hearing date has recently been adjourned and no new hearing date has been scheduled. The individual case in Ontario requests damages in excess of $1 million (claiming unspecified special damages, health care costs and interest). Based on the Company’s historical experience, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed. To the extent that the Company’s future Silzone costs (inclusive of settlements, judgments, legal fees and other related defense costs) exceed its remaining historical insurance coverage of approximately $10 million, the Company would be responsible for such costs.

The Company intends to vigorously defend against the claims that have been asserted. The Company has not recorded an expense related to any potential damages in connection with these product liability litigation matters because any potential loss is not probable or reasonably estimable. Other than disclosed above, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these litigation matters.

Patent and Other Intellectual Property Litigation

Volcano Corporation & LightLab Imaging Litigation: The Company's subsidiary, LightLab Imaging, has pending litigation with Volcano Corporation (Volcano) and Axsun Technologies, Inc. (Axsun), a subsidiary of Volcano, in the Massachusetts state court and in state court in Delaware. LightLab Imaging makes and sells optical coherence tomography (OCT) imaging systems. Volcano is a LightLab Imaging competitor in medical imaging. Axsun makes and sells lasers and is a supplier of lasers to LightLab Imaging for use in OCT imaging systems. The lawsuits arise out of Volcano's acquisition of Axsun in December 2008. Before Volcano acquired Axsun, LightLab Imaging and Axsun had worked together to develop a tunable laser for use in OCT imaging systems. While the laser was in development, LightLab Imaging and Axsun entered into an agreement pursuant to which Axsun agreed to sell its tunable lasers exclusively to LightLab in the field of human coronary artery imaging for a certain period of time.

After Volcano acquired Axsun in December 2008, LightLab Imaging sued Axsun and Volcano in Massachusetts, asserting a number of claims arising out of Volcano's acquisition of Axsun. In January 2011, the Court ruled that Axsun's and Volcano's conduct constituted knowing and willful violations of a statute which prohibits unfair or deceptive acts or practices or acts of unfair competition, entitling LightLab Imaging to double damages, and furthermore, that LightLab Imaging was entitled to recover attorneys' fees. In February 2011, Volcano and Axsun were ordered to pay the Company for reimbursement of attorneys' fees and double damages, which Volcano paid to the Company in July 2011. The Court also issued certain injunctions and declaratory relief against Volcano. The Company has also appealed certain rulings relating to the trial court's exclusion of certain expert testimony and its refusal to enter permanent injunctions. In January 2013, the Supreme Judicial Court for Massachusetts granted the Company's request to bypass the intermediary appellate court and has accepted the matter for its direct review. Oral argument has been scheduled for December 2, 2013, and the appeal is expected to be finalized in 2014.

In May 2011, LightLab Imaging initiated a lawsuit against Volcano and Axsun in the Delaware state court. The suit seeks to enforce LightLab Imaging's exclusive contract with Axsun, and also alleges claims to prevent Volcano from interfering with that contract and to bar Axsun and Volcano from using LightLab Imaging confidential information and trade secrets, and to prevent Volcano and Axsun from violating a Massachusetts statute prohibiting unfair methods of competition and unfair or deceptive acts or practices relating to LightLab Imaging's tunable laser technology. In May 2012, the Court granted Volcano's motion to stay the proceedings until Volcano provides notice of its intent to begin clinical trials or engage in other public activities with an OCT imaging system that uses a type of light source that is in dispute in the lawsuit. Volcano is under an order to provide such a notice at least 45 days before beginning such trials or engaging in such activities. In April 2013, the Court denied a motion by the Company to lift the stay.

Volcano Corporation & St. Jude Medical Patent Litigation: In July 2010, the Company filed a lawsuit in federal district court in Delaware against Volcano for patent infringement. In the suit, the Company asserted certain patents against Volcano and seeks injunctive relief and monetary damages. The infringed patents are part of the St. Jude Medical PressureWire® technology platform, which was acquired as part of St. Jude Medical's purchase of Radi Medical Systems in December 2008. On October 19, 2012 a jury ruled in favor of Volcano finding that certain Volcano patents did not infringe the Company's patents and that certain St. Jude Medical patents were invalid. The Company has filed a motion for judgment as a matter of law and for a new trial. If necessary, the Company will appeal to the appellate court and raise challenges to various issues related to the trial that resulted in the October 19, 2012 jury decision. Volcano also filed counterclaims against the Company in this case, alleging certain St. Jude Medical patent claims are unenforceable and that certain St. Jude Medical products infringe certain Volcano patents. On October 25, 2012, a jury ruled that the Company did not infringe certain Volcano patents and entered judgment on both October jury verdicts in January 2013. The parties are moving forward with other post-trial proceedings.

On April 16, 2013, Volcano filed a lawsuit in federal district court in Delaware against the Company alleging that the Company is infringing two U.S. patents owned by Volcano which were issued that same day. The allegations relate to the Company's PressureWire® technology (Fractional Flow Reserve) FFR Platforms, including ILUMIENTM PCI Optimization System and QuantienTM Integrated FFR platforms. In its complaint, Volcano seeks both injunctive relief and monetary damages. A hearing on claims construction has been scheduled for November 2013. The Company plans to vigorously defend against the claims asserted. The Company has not recorded an expense related to any potential damages in connection with this litigation matter because any potential loss is not probable or reasonably estimable. Other than disclosed above, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these litigation matters.

Securities and Other Shareholder Litigation

March 2010 Securities Class Action Litigation: In March 2010, a securities lawsuit seeking class action status was filed in federal district court in Minnesota against the Company and certain officers (collectively, the defendants) on behalf of purchasers of St. Jude Medical common stock between April 22, 2009 and October 6, 2009. The lawsuit relates to the Company's earnings announcements for the first, second and third quarters of 2009, as well as a preliminary earnings release dated October 6, 2009. The complaint, which seeks unspecified damages and other relief as well as attorneys' fees, alleges that the defendants failed to disclose that it was experiencing a slowdown in demand for its products and was not receiving anticipated orders for cardiac rhythm management devices. Class members allege that the defendant's failure to disclose the above information resulted in the class purchasing St. Jude Medical stock at an artificially inflated price. In December 2011, the Court issued a decision denying a motion to dismiss filed by the defendants in October 2010. In October 2012, the Court granted plaintiffs' motion to certify the case as a class action and the discovery phase of the case closed in September 2013. On October 15, 2013, the defendants filed a motion for summary judgment and a hearing is scheduled for January 2014 and a ruling is expected later in 2014. Subject to the outcome of this hearing, the trial of this class action matter is presently scheduled for July 2014. The defendants intend to continue to vigorously defend against the claims asserted in this lawsuit.

December 2012 Securities Class Action Litigation: On December 7, 2012, a securities class action lawsuit was filed

in federal district court in Minnesota against the Company and an officer (collectively, the defendants) for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the defendants between October 17, 2012 and November 20, 2012. The complaint, which seeks unspecified damages and other relief as well as attorneys' fees, challenges the Company’s disclosures concerning its high voltage cardiac rhythm lead products during the purported class period. On December 10, 2012, a second securities class action lawsuit was filed in federal district court in Minnesota against the Company and certain officers for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the Company between October 19, 2011 and November 20, 2012. The second complaint pursues similar claims and seeks unspecified damages and other relief as well as attorneys’ fees. In March 2013, the Court consolidated the two cases and appointed a lead counsel and lead plaintiff. In September 2013, the defendants filed a motion to dismiss the consolidated and amended complaint. Oral argument concerning this motion to dismiss is scheduled for early January 2014, and a ruling is expected later in 2014. The Company intends to vigorously defend against the claims asserted in this matter.

December 2012 Derivative Litigation: In December 2012, a shareholder derivative action was initiated in Minnesota state court in Ramsey County, on behalf of the Company, against members of St. Jude Medical’s Board of Directors as well as certain officers of the Company (collectively, the defendants). The plaintiffs in this action allege breach of fiduciary duty, waste of corporate assets and unjust enrichment. The claims center around and involve the Company’s high voltage cardiac rhythm lead products and related activities and events. No damages are sought against the Company. The defendants intend to vigorously defend against the claims asserted in this matter. In March 2013, the defendants filed a motion to dismiss the plaintiffs' complaint. No hearing on the motion has yet been scheduled.

The Company has not recorded an expense related to any potential damages in connection with these securities and other shareholder litigation matters because any potential loss is not probable or reasonably estimable. The Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters.

Governmental Investigations

In March 2010, the Company received a Civil Investigative Demand (CID) from the Civil Division of the Department of Justice (DOJ). The CID requests documents and sets forth interrogatories related to communications by and within the Company on various indications for tachycardia implantable cardioverter defibrillator systems (ICDs) and a National Coverage Decision issued by Centers for Medicare and Medicaid Services. Similar requests were made of the Company's major competitors. The Company provided its response to the DOJ in June 2010.

On September 20, 2012, the Office of Inspector General for the Department of Health and Human Services (OIG) issued a subpoena requiring the Company to produce certain documents related to payments made by the Company to healthcare professionals practicing in California, Florida, and Arizona, as well as policies and procedures related to payments made by the Company to non-employee healthcare professionals. The Company has provided its response to the OIG.

The Company is cooperating with the two open investigations and is responding to these requests. However, the Company cannot predict when these investigations will be resolved, the outcome of these investigations or their impact on the Company. The Company has not recorded an expense related to any potential damages in connection with these governmental matters because any potential loss is not probable or reasonably estimable. The Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters.

Regulatory Matters

In late September 2012, the FDA commenced an inspection of the Company's Sylmar, California facility, and, following such inspection, issued eleven observations on a Form 483, which the Company disclosed on a Form 8-K filed on October 24, 2012 along with an exhibit containing a redacted version of the Form 483. The FDA subsequently released its own redacted version of the 483 Letter on November 20, 2012. The redacted version of the Form 483 that was released by the FDA on November 20, 2012 and included in its website at that time is attached as Exhibit 99.1 to the Company's Quarterly Report on Form 10-Q for the period ended June 29, 2013. In early November 2012, the Company provided written responses to the FDA on the Form 483 detailing proposed corrective actions and immediately initiated efforts to address the FDA's inspectional observations. The Company subsequently received a warning letter dated January 10, 2013 from the FDA relating to these inspectional observations with respect to its Sylmar, California facility. The warning letter does not identify any specific concerns regarding the performance of, or indicate the need for any field or other action regarding, any particular St. Jude Medical product. In July 2013, the FDA inspected the Company's Sylmar, California facility for progress made remediating the warning letter and Form 483 observations. No additional observations on Form 483 were issued following the July inspection. The Sylmar, California facility will continue to manufacture cardiac rhythm management devices while the Company works with the FDA to address its concerns.

The FDA inspected the Company's Plano, Texas manufacturing facility at various times between March 5 and April 6, 2009. On April 6, 2009, the FDA issued a Form 483 identifying certain inspectional observations with current Good Manufacturing Practice (cGMP). Following the receipt of the Form 483, the Company provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address the FDA's inspectional observations. The Company subsequently received a warning letter dated June 26, 2009 from the FDA relating to these inspectional observations with respect to its legacy Neuromodulation division's Plano, Texas and Hackettstown, New Jersey facilities.

With respect to both of these warning letters, the FDA notes that it will not grant requests for exportation certificates to foreign governments or approve pre-market approval applications for Class III devices to which the quality system regulation deviations are reasonably related until the violations have been corrected. The Company is working cooperatively with the FDA to resolve all of its concerns.

Customer orders have not been and are not expected to be impacted while the Company works to resolve the FDA's concerns. The Company is working diligently to respond timely and fully to the FDA's observations and requests. While the Company believes the issues raised by the FDA can be resolved without a material impact on the Company's financial results, the FDA has recently been increasing its scrutiny of the medical device industry and raising the threshold for compliance. The government is expected to continue to scrutinize the industry closely with inspections, and possibly enforcement actions, by the FDA or other agencies. The Company is regularly monitoring, assessing and improving its internal compliance systems and procedures to ensure that its activities are consistent with applicable laws, regulations and requirements, including those of the FDA.

Product Warranties

The Company offers a warranty on various products, the most significant of which relates to its ICDs and pacemakers systems. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Factors that affect the Company’s warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

Changes in the Company’s product warranty liability during the three and nine months ended September 28, 2013 and September 29, 2012 were as follows (in millions):

Three Months Ended

Nine Months Ended

September 28, 2013

September 29, 2012

September 28, 2013

September 29, 2012

Balance at beginning of period

$

37

$

38

$

38

$

36

Warranty expense recognized

(2

)

2

1

5

Warranty credits issued

—

(1

)

(4

)

(2

)

Balance at end of period

$

35

$

39

$

35

$

39

Special_Charges

Special Charges	9 Months Ended
	Sep. 28, 2013
Special Charges [Abstract]	'
Special Charges	'
	SPECIAL CHARGES
	The Company recognizes certain transactions and events as special charges in its consolidated financial statements. These charges (such as restructuring charges, impairment charges and certain settlement or litigation charges) result from facts and circumstances that vary in frequency and impact on the Company's results of operations. In order to enhance segment comparability and reflect management's focus on the ongoing operations of the Company, special charges are not reflected in the individual reportable segments operating results.
	2012 Business Realignment Plan
	During 2012, the Company incurred charges of $185 million resulting from the realignment of its product divisions into two new operating divisions: the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes are part of a comprehensive plan to accelerate the Company's growth, reduce costs, leverage economies of scale and increase investment in product development. In connection with the realignment, the Company recognized $109 million of severance costs and other termination benefits after management determined that such severance and benefit costs were probable and estimable, in accordance with ASC Topic 712, Nonretirement Postemployment Benefits (ASC Topic 712). The 2012 business realignment plan reduced the Company's workforce by approximately 5%. The Company also recognized $17 million of inventory write-offs associated with discontinued CATD product lines and $41 million of accelerated depreciation charges and fixed asset write-offs, primarily associated with information technology assets no longer expected to be utilized or with a limited remaining useful life. Additionally, the Company recognized $18 million of other restructuring costs, which included $7 million of contract termination costs and $11 million of other costs.
	During the first quarter of 2013, the Company incurred $34 million of special charges associated with the 2012 business realignment plan including $10 million of severance and other termination benefits after management determined that such costs were probable and estimable. The Company also recognized $18 million of inventory write-offs associated with discontinued CATD product lines, $2 million of fixed asset write-offs and $4 million of other restructuring costs, all as part of the Company's continued integration efforts.
	During the second quarter of 2013, the Company recognized $39 million of special charges associated with the 2012 business realignment plan including $19 million of severance and other termination benefits after management determined that such costs were probable and estimable in accordance with ASC Topic 712. The Company also recognized $1 million of inventory write-offs primarily associated with discontinued IESD product lines, $2 million of fixed asset write-offs related to information technology assets no longer expected to be utilized and $17 million of other restructuring costs primarily related to distributor terminations and office consolidations, all as part of the Company's continued integration efforts.
	During the third quarter of 2013, the Company recognized $13 million of special charges related to the 2012 business realignment plan. Of the $13 million recognized, $7 million related to other restructuring costs primarily associated with distributor terminations and office consolidations, $4 million related to severance and other termination benefits after management determined that such costs were probable and estimable in accordance with ASC Topic 712 and $2 million related to inventory write-offs associated with discontinued CATD product lines.
	A summary of the activity related to the 2012 business realignment plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 31, 2011	$	—		$	—		$	—		$	—		$	—
	Cost of sales special charges	5			17			—			2			24
	Special charges	104			—			41			16			161
	Non-cash charges used	—			(17		)	(41		)	(3		)	(61		)
	Cash payments	(52		)	—			—			(7		)	(59		)
	Foreign exchange rate impact	1			—			—			—			1
	Balance at December 29, 2012	58			—			—			8			66
	Cost of sales special charges	—			18			—			—			18
	Special charges	10			—			2			4			16
	Non-cash charges used	—			(18		)	(2		)	—			(20		)
	Cash payments	(32		)	—			—			(3		)	(35		)
	Foreign exchange rate impact	(1		)	—			—			—			(1		)
	Balance at March 30, 2013	35			—			—			9			44
	Cost of sales special charges	—			1			—			—			1
	Special charges	19			—			2			17			38
	Non-cash charges used	—			(1		)	(2		)	(4		)	(7		)
	Cash payments	(17		)	—			—			(9		)	(26		)
	Foreign exchange rate impact	1			—			—			—			1
	Balance at June 29, 2013	38			—			—			13			51
	Cost of sales special charges	—			2			—			—			2
	Special charges	4			—			—			7			11
	Non-cash charges used	—			(2		)	—			—			(2		)
	Cash payments	(15		)	—			—			(7		)	(22		)
	Foreign exchange rate impact	—			—			—			—			—
	Balance at September 28, 2013	$	27		$	—		$	—		$	13		$	40
	2011 Restructuring Plan
	During 2011, the Company announced a restructuring plan to streamline certain activities in the Company's legacy cardiac rhythm management business and sales and selling support organizations. Specifically, the restructuring actions included phasing out cardiac rhythm management manufacturing and research and development (R&D) operations in Sweden, reductions in the Company's workforce and rationalizing product lines. During 2011, the Company incurred charges totaling $162 million related to the 2011 restructuring plan. During 2012, the Company incurred additional charges totaling $102 million related to the 2011 restructuring plan consisting of severance costs and other termination benefits of $38 million, $13 million of inventory obsolescence charges and $51 million of other restructuring charges, which included $37 million of restructuring related charges associated with the Company's legacy cardiac rhythm management business and sales and selling support organizations (of which $13 million primarily related to idle facility costs in Sweden). The remaining charges included $8 million of contract termination costs and $6 million of other costs.
	During the first quarter of 2013, the Company recognized $9 million of restructuring charges associated with the 2011 restructuring plan. Of the $9 million incurred, $2 million related to severance costs and other termination benefits and $7 million related to other restructuring costs, primarily associated with idle facility costs.
	During the second quarter of 2013, the Company recognized $4 million of restructuring charges associated with the 2011 restructuring plan. Of the $4 million recognized, $1 million related to fixed asset write-offs as the Company finalizes the phase-out of operations in Sweden and $3 million related to other restructuring costs, primarily associated with idle facility costs.
	During the third quarter of 2013, the Company recognized $6 million of restructuring charges associated with the 2011 restructuring plan. Of the $6 million recognized, $2 million related to severance costs and other termination benefits and $4 million related to other restructuring costs, primarily associated with idle facility costs.
	A summary of the activity related to the 2011 restructuring plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 31, 2011	$	54		$	—		$	—		$	18		$	72
	Cost of sales special charges	11			13			—			20			44
	Special charges	27			—			—			31			58
	Non-cash charges used	—			(13		)	—			(4		)	(17		)
	Cash payments	(68		)	—			—			(47		)	(115		)
	Foreign exchange rate impact	1			—			—			(1		)	—
	Balance at December 29, 2012	25			—			—			17			42
	Special charges	2			—			—			7			9
	Cash payments	(13		)	—			—			(6		)	(19		)
	Balance March 30, 2013	14			—			—			18			32
	Special charges	—			—			1			3			4
	Non-cash charges used	—			—			(1		)	—			(1		)
	Cash payments	(5		)	—			—			(7		)	(12		)
	Balance at June 29, 2013	9			—			—			14			23
	Special charges	2			—			—			4			6
	Cash payments	(1		)	—			—			(5		)	(6		)
	Balance at September 28, 2013	$	10		$	—		$	—		$	13		$	23
	Other Special Charges
During the second quarter of 2013, the Company agreed to settle a dispute on licensed technology associated with certain CATD product lines. In connection with the settlement, which resolved all disputed claims, the Company recognized a $22 million settlement expense. Also during the second quarter of 2013, the Company recognized $13 million of impairments associated with customer relationship intangible assets recognized in connection with legacy acquisitions involved in the distribution of the Company's products.
During the first nine months of 2012, the Company recognized a $23 million impairment charge for certain developed technology intangible assets in its neuromodulation business as the Company's updated expectations for the future undiscounted cash flows did not exceed the carrying value of the related assets. Additionally, the Company determined that certain CATD intangible assets were considered impaired as their future expected undiscounted cash flows did not exceed the carrying value of the related assets. As a result, the Company recognized a $5 million impairment charge to write-down the intangible assets to their fair value. The Company also agreed to settle a dispute on licensed technology for its Angio-Seal™ vascular closure devices. In connection with this settlement, which resolved all disputed claims and included a fully-paid perpetual license, the Company recognized a $28 million settlement expense which it classified as a special charge and also recognized a $12 million licensed technology intangible asset to be amortized over the technology's remaining patent life.

Net_Earnings_Per_Share

Net Earnings Per Share	9 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]	'
Net Earnings Per Share	'
	NET EARNINGS PER SHARE
	The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts):
		Three Months Ended				Nine Months Ended
		September 28, 2013		September 29, 2012		September 28, 2013		September 29, 2012
	Numerator:
	Net earnings attributable to St. Jude Medical, Inc.	$	262	$	176	$	600	$	632
	Denominator:
	Basic weighted average shares outstanding	287.5		314.7		285.6		314.8
	Effect of dilutive securities:
	Employee stock options	4		1.3		2.8		1.4
	Restricted stock units	0.5		0.3		0.3		0.2
	Diluted weighted average shares outstanding	292		316.3		288.7		316.4
	Basic net earnings per share attributable to St. Jude Medical, Inc.	$	0.91	$	0.56	$	2.1	$	2.01
	Diluted net earnings per share attributable to St. Jude Medical, Inc.	$	0.9	$	0.56	$	2.08	$	2
	Approximately 2.2 million and 16.1 million shares of common stock subject to stock options and restricted stock units were excluded from the diluted net earnings per share computation for the three months ended September 28, 2013 and September 29, 2012, respectively, because they were not dilutive. Additionally, approximately 5.4 million and 16.7 million shares of common stock subject to stock options and restricted stock units were excluded from the diluted net earnings per share computation for the nine months ended September 28, 2013 and September 29, 2012, respectively, because they were not dilutive.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 28, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
	The tables below present the changes in each component of accumulated other comprehensive income, including other comprehensive income and reclassifications out of accumulated other comprehensive income in to net earnings for the three and nine months ended September 28, 2013 (in millions):
		Unrealized			Unrealized			Foreign			Accumulated
		gain (loss) on			gain (loss) on			Currency			Other
		available-for-sale			derivative			Translation			Comprehensive
	For the three months ended September 28, 2013	securities			instruments			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at June 29, 2013	$	18		$	3		$	(15	)	$	6
	Other comprehensive income (loss) before reclassifications	—			—			51			51
	Amounts reclassified to net earnings from accumulated other comprehensive income	(2		)	—			—			(2		)
	Other comprehensive income (loss)	(2		)	—			51			49
	Accumulated other comprehensive income (loss), net of tax, at September 28, 2013	$	16		$	3		$	36		$	55
		Unrealized			Unrealized			Foreign			Accumulated
		gain (loss) on			gain (loss) on			Currency			Other
		available-for-sale			derivative			Translation			Comprehensive
	For the nine months ended September 28, 2013	securities			instruments			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at December 29, 2012	$	20		$	—		$	26		$	46
	Other comprehensive income (loss) before reclassifications	1			3			10			14
	Amounts reclassified to net earnings from accumulated other comprehensive income	(5		)	—			—			(5		)
	Other comprehensive income (loss)	(4		)	3			10			9
	Accumulated other comprehensive income (loss), net of tax, at September 28, 2013	$	16		$	3		$	36		$	55
	The tables below present the changes in each component of accumulated other comprehensive income, including other comprehensive income and reclassifications out of accumulated other comprehensive income in to net earnings for the three and nine months ended September 29, 2012 (in millions):
		Unrealized			Foreign			Accumulated
		gain (loss) on			Currency			Other
		available-for-sale			Translation			Comprehensive
	For the three months ended September 29, 2012	securities			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at June 30, 2012	$	19		$	(48	)	$	(29	)
	Other comprehensive income (loss) before reclassifications	4			44			48
	Amounts reclassified to net earnings from accumulated other comprehensive income	(3		)	—			(3		)
	Other comprehensive income (loss)	1			44			45
	Accumulated other comprehensive income (loss), net of tax, at September 29, 2012	$	20		$	(4	)	$	16
		Unrealized			Foreign			Accumulated
		gain (loss) on			Currency			Other
		available-for-sale			Translation			Comprehensive
	For the nine months ended September 29, 2012	securities			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at December 31, 2011	$	18		$	(2	)	$	16
	Other comprehensive income (loss) before reclassifications	10			(2		)	8
	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			(8		)
	Other comprehensive income (loss)	2			(2		)	—
	Accumulated other comprehensive income (loss), net of tax, at September 29, 2012	$	20		$	(4	)	$	16
	The table below provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings for the three and nine months ended September 28, 2013 and September 29, 2012 (in millions):
	Details about accumulated	Amount reclassified from accumulated other comprehensive income
	other comprehensive	Three Months Ended						Nine Months Ended
	income components	September 28, 2013			September 29, 2012			September 28, 2013			September 29, 2012			Statements of Earnings Classification
	Unrealized gain (loss) on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	4		$	5		$	9		$	14		Other expense, net
		(2		)	(2		)	(4		)	(6		)	Income tax expense
		2			3			5			8			Net earnings before noncontrolling interest
		$	2		$	3		$	5		$	8		Net earnings attributable to St. Jude Medical, Inc.

Other_Expense_Net

Other Expense, Net	9 Months Ended
	Sep. 28, 2013
Other Nonoperating Income (Expense) [Abstract]	'
Other Expense, Net	'
	OTHER EXPENSE, NET
	The Company’s other expense, net consisted of the following (in millions):
		Three Months Ended						Nine Months Ended
		September 28, 2013			September 29, 2012			September 28, 2013			September 29, 2012
	Interest income	$	(1	)	$	(1	)	$	(4	)	$	(3	)
	Interest expense	21			18			60			55
	Other	(3		)	2			192			15
	Other expense, net	$	17		$	19		$	248		$	67
	During the second quarter of 2013, the Company redeemed the full $700 million principal amount of the 2014 Senior Notes and the full $500 million principal amount of the 2019 Senior Notes. In connection with the redemption of these notes, prior to their scheduled maturities, the Company recognized a $161 million charge to other expense associated with make-whole redemption payments and the write-off of unamortized debt issuance costs (see Note 5).
	During the first quarter of 2013, the Company recorded a $29 million charge to other expense to adjust the carrying value of the pre-existing CardioMEMS equity investment and fixed price purchase option to fair value. See Note 2 for further detail on the accounting for CardioMEMS as a variable interest entity, which has been consolidated into the Company's results in the first quarter of 2013.

Income_Taxes

Income Taxes	3 Months Ended
	Sep. 28, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	As of September 28, 2013, the Company had $265 million accrued for unrecognized tax benefits, all of which would affect the Company’s effective tax rate if recognized. Additionally, the Company had $35 million accrued for interest and penalties as of September 28, 2013. At December 29, 2012, the liability for unrecognized tax benefits was $314 million and the accrual for interest and penalties was $69 million. The Company recognizes interest and penalties related to income tax matters in income tax expense.
	The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company has substantially concluded all material U.S. federal, state, foreign and local income tax matters for all tax years through 2004. The U.S. Internal Revenue Service (IRS) is currently auditing the Company’s 2008 and 2009 tax returns and an audit report is expected to be issued in 2013. In 2012, the Company recognized $46 million of additional tax expense related to a settlement reserve for certain prior period tax positions related to the 2002 through 2009 tax years. During the third quarter of 2013, the Company recognized a $15 million tax settlement benefit due to the resolution of the IRS audits of the 2002 through 2007 tax years. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months.

Fair_Value_Measurements_And_Fi

Fair Value Measurements And Financial Instruments	9 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements And Financial Instruments	'
	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS
	The fair value measurement accounting standard, codified in ASC Topic 820, Fair Value Measurement (ASC Topic 820), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The categories within the valuation hierarchy are described as follows:
	•	Level 1 – Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
	•	Level 2 – Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
	•	Level 3 – Inputs to the fair value measurement are unobservable inputs or valuation techniques.
	Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
	The fair value measurement standard applies to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). These financial assets and liabilities include money-market securities, trading marketable securities, available-for-sale marketable securities, derivative instruments and contingent consideration liabilities. The Company continues to record these items at fair value on a recurring basis and the fair value measurements are applied using ASC Topic 820. The Company does not have any material nonfinancial assets or liabilities that are measured at fair value on a recurring basis. A summary of the valuation methodologies used for the respective financial assets and liabilities measured at fair value on a recurring basis is as follows:
	Money-Market Securities: The Company’s money-market securities include funds that are traded in active markets and are recorded at fair value based upon the quoted market prices. The Company classifies these securities as level 1.
	Trading Securities: The Company’s trading securities include publicly-traded mutual funds that are traded in active markets and are recorded at fair value based upon quoted market prices of the net asset values of the funds. The Company classifies these securities as level 1.
	Available-For-Sale Securities: The Company’s available-for-sale securities include publicly-traded equity securities that are traded in active markets and are recorded at fair value based upon the closing stock prices. The Company classifies these securities as level 1.
	The following table summarizes the components of the balance of the Company’s available-for-sale securities at September 28, 2013 and December 29, 2012 (in millions):
		September 28, 2013				December 29, 2012
	Adjusted cost	$	7			$	9
	Gross unrealized gains	26				32
	Fair value	$	33			$	41
	Derivative Instruments: The Company’s derivative instruments consist of foreign currency exchange contracts. The Company classifies these instruments as level 2 as the fair value is determined using inputs other than observable quoted market prices. These inputs include spot and forward foreign currency exchange rates that the Company obtains from standard market data providers. The fair value of the Company’s outstanding foreign currency exchange contracts was not material at September 28, 2013 or December 29, 2012.
	Contingent Consideration Liabilities: In connection with certain business combinations or purchases of intellectual property the Company may agree to provide potential future contingent consideration payments upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. Contingent consideration is recorded at the estimated fair value of the contingent milestone payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within other expense, net in the Condensed Consolidated Statements of Earnings. The Company measures the liability on a recurring basis using Level 3 inputs including projected revenues, discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a probability weighted discounted cash flow model. Projected revenues are based on the Company's most recent internal operating budgets and long-term strategic plans. Increases or decreases to any of the inputs may result in significantly higher or lower fair value measurements.
	A summary of financial assets measured at fair value on a recurring basis at September 28, 2013 and December 29, 2012 is as follows (in millions):
		Balance Sheet	September 28, 2013				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	848			$	848			$	—	$	—
	Available-for-sale securities	Other current assets	33				33				—		—
	Trading securities	Other assets	254				254				—		—
	Total assets		$	1,135			$	1,135			$	—	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	136			$	—			$	—	$	136
	Total liabilities		$	136			$	—			$	—	$	136
		Balance Sheet	December 29, 2012				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	964			$	964			$	—	$	—
	Available-for-sale securities	Other current assets	41				41				—		—
	Trading securities	Other assets	231				231				—		—
	Total assets		$	1,236			$	1,236			$	—	$	—
	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs (in millions):
	Contingent Consideration Liability	Fair Value as of September 28, 2013			Valuation Technique		Unobservable Input		Range
	Endosense regulatory-based milestone	$	136		Probability Weighted Discounted Cash Flow		Discount Rate		1.15%	-	1.71%
							Probability of Payment				90%
							Projected Year of Payment				2014
	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's contingent consideration liability associated with its Endosense acquisition subsequent to August 19, 2013 as of September 28, 2013 (in millions):
		Fiscal Year 2013
	Beginning balance	$	—
	Purchase price contingent consideration	132
	Change in fair value of contingent consideration	1
	Foreign currency translation	3
	Ending balance	$	136
	Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
	The fair value measurement standard also applies to certain nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies used for the respective nonfinancial assets and liabilities measured at fair value on a nonrecurring basis is as follows:
	Long-Lived Assets: The Company reviews the carrying amount of its long-lived assets other than goodwill and indefinite-lived intangible assets for potential impairment whenever events or changes in circumstance include a significant decrease in market price, a significant adverse change in the extent or manner in which an asset is being used or a significant adverse change in the legal or business climate. The Company measures the fair value of its long-lived assets, such as its definite-lived intangible assets and property, plant and equipment using independent appraisals, market models and discounted cash flow models. A discounted cash flow model requires inputs to a present value cash flow calculation such as a risk-adjusted discount rate, terminal values, operating budgets, long-term strategic plans and remaining useful lives of the asset or asset group. If the carrying value of the Company’s long-lived assets (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted future cash flows, the carrying value is written down to the fair value in the period identified.
	During the second quarter of 2013, the Company recognized $13 million of impairments associated with customer relationship intangible assets, as it determined that these intangible assets had no discrete future cash flows and were fully impaired. Refer to Note 7 for further details of these charges.
	During the third quarter of 2012, the Company determined that certain purchased technology intangible assets in the Company's neuromodulation business were considered impaired as their future expected undiscounted cash flows did not exceed the carrying value of the related assets. As a result, the Company recognized a $23 million impairment charge to write-down the intangible assets to their estimated fair value of $3 million as of September 29, 2012. The fair value measurements of these intangible assets are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs, specifically the discounted cash flows income approach method, to measure fair value.
	During the second quarter of 2012, the Company determined that certain purchased technology intangible assets in CATD were considered impaired as their future expected undiscounted cash flows did not exceed the carrying value of the related assets. As a result, the Company recognized a $5 million impairment charge to write-down the intangible assets to their estimated fair value of $4 million as of June 30, 2012. The fair value measurements of these intangible assets are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs, specifically the discounted cash flows income approach method, to measure fair value. The product lines were later discontinued in the fourth quarter of 2012, and the related remaining intangible asset value was fully impaired as there were no discrete future cash flows.
	Cost Method Investments: The Company also holds investments in equity securities that are accounted for as cost method investments, which are classified as other assets and measured at fair value on a nonrecurring basis. The fair value of the Company’s cost method investments is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of these investments. When measured on a nonrecurring basis, the Company’s cost method investments are considered Level 3 in the fair value hierarchy due to the use of unobservable inputs to measure fair value.
	The carrying value of these investments approximated $101 million and $151 million as of September 28, 2013 and December 29, 2012, respectively. The decrease in the Company's cost method investments since December 29, 2012 was primarily due to the consolidation of CardioMEMS and the elimination of the pre-existing equity investment which had been previously accounted for as a cost method investment. Effective February 27, 2013, the Company determined that CardioMEMS was a VIE for which the Company is considered the primary beneficiary (see Note 2).
	Fair Value Measurements of Other Financial Instruments
The aggregate fair value of the Company’s fixed-rate senior notes at September 28, 2013 (measured using quoted prices in active markets) was $2,269 million compared to the aggregate carrying value of $2,317 million (inclusive of the terminated interest rate swaps). The fair value of the Company’s variable-rate debt obligations at September 28, 2013 approximated its aggregate $1,152 million carrying value due to the variable interest rate and short-term nature of these instruments.

Derivative_Financial_Instrumen

Derivative Financial Instruments	9 Months Ended
	Sep. 28, 2013
General Discussion of Derivative Instruments and Hedging Activities [Abstract]	'
Derivative Financial Instruments	'
	DERIVATIVE FINANCIAL INSTRUMENTS
	The Company follows the provisions of ASC Topic 815, Derivatives and Hedging (ASC Topic 815) in accounting for and disclosing derivative instruments and hedging activities. All derivative financial instruments are recognized on the balance sheet at fair value. Changes in the fair value of derivatives are recognized in net earnings or other comprehensive income depending on whether the derivative is designated as part of a qualifying hedge transaction. Derivative assets and derivative liabilities are classified as other current assets, other assets, other current liabilities or other liabilities, as appropriate.
	Foreign Currency Forward Contracts
	The Company hedges a portion of its foreign currency exchange rate risk through the use of forward exchange contracts. The Company uses forward exchange contracts to manage foreign currency exposures related to intercompany receivables and payables arising from intercompany purchases of manufactured products. These forward contracts are not designated as qualifying hedging relationships under ASC Topic 815. The Company measures its foreign currency exchange contracts at fair value on a recurring basis. The fair value of outstanding contracts was immaterial as of September 28, 2013 and December 29, 2012. During the third quarter of 2013 the amount of net losses the Company recorded to other expense for its forward currency exchange contracts not designated as hedging instruments under ASC Topic 815 was insignificant. During the third quarter of 2012 the amount of net losses the Company recorded to other expense for its forward currency exchange contracts not designated as hedging instruments under ASC Topic 815 was a net loss of $4 million. During the first nine months of 2013 and 2012, the net amount of gains the Company recorded to other expense for its forward currency exchange contracts not designated as hedging instruments under ASC Topic 815 were net gains of $13 million and $1 million, respectively. These net gains/losses were almost entirely offset by corresponding net losses/gains on the foreign currency exposures being managed. The Company does not enter into contracts for trading or speculative purposes. The Company’s policy is to enter into hedging contracts with major financial institutions that have at least an “A” (or equivalent) credit rating.
	Interest Rate Contracts
	During the first quarter of 2013, the Company entered into and settled treasury rate lock agreements in anticipation of issuing $900 million principal amount of 10-year senior notes and $700 million principal amount of 30-year senior notes. Prior to the issuance of the senior notes, the Company was subject to changes in treasury benchmark interest rates, and therefore locked into fixed-rate coupons to hedge against the interest rate fluctuations. The Company designated the treasury rate lock agreements as cash flow hedges under ASC Topic 815. Upon settlement, the $3 million gain was recognized as a component of other comprehensive income, and will be recognized as a reduction to interest expense over the life of the senior notes. The amount of hedge ineffectiveness was immaterial.
	In prior periods, the Company has chosen to hedge the fair value of certain debt obligations through the use of interest rate swap contracts. For interest rate swap contracts that are designated and qualify as fair value hedges, changes in the value of the fair value hedge are recognized as an asset or liability, as applicable, offsetting the changes in the fair value of the hedged debt instrument. When outstanding, the Company’s swap contracts are recorded on the consolidated balance sheet as a component of other current assets, other assets, other accrued expenses or other liabilities based on the gain or loss position of the contract and the contract maturity date. Additionally, any payments made or received under the swap contracts are accrued and recognized as interest expense. In June 2012, the Company terminated the interest rate swap it had entered into concurrent with the March 2010 issuance of the 2016 Senior Notes and received a cash payment of $24 million. The gain from terminating the interest rate swap agreement has been reflected as an increase to the carrying value of the debt and is being amortized as a reduction of interest expense resulting in a net average interest rate of 1.3% that will be recognized over the remaining term of the 2016 Senior Notes.

Segment_And_Geographic_Informa

Segment And Geographic Information	9 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Segment And Geographic Information	'
	SEGMENT AND GEOGRAPHIC INFORMATION
	Segment Information
	On August 30, 2012, the Company announced the realignment of its product divisions into two new business units (or divisions): the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes were part of a comprehensive plan to accelerate our growth, reduce costs, leverage economies of scale and increase investment in product development. The Company began reporting under the new organizational structure as of the beginning of fiscal year 2013. Prior period amounts in the tables below have been recast to conform to the Company's new reportable segment structure.
	The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) – tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) – vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems).
	IESD and CATD are considered the Company's reportable segments. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products they each develop and manufacture or distribute. The costs included in each of the reportable segments’ operating results include the direct costs of the products sold to customers and operating expenses managed by each of the reportable segments. Certain expenses managed by the Company’s selling and corporate functions, including all stock-based compensation expense, impairment charges, certain acquisition-related charges, IPR&D charges, excise tax expense, special charges and centralized support groups' operating expenses are not recorded in the IESD and CATD reportable segments. As a result, reportable segment operating profit is not representative of the operating profit of the products in these reportable segments. Additionally, certain assets are managed by the Company’s selling and corporate functions, principally including trade receivables, inventory, cash and cash equivalents, certain marketable securities and certain deferred income taxes. For management reporting purposes, the Company does not compile capital expenditures by reportable segment; therefore, this information has not been presented, as it is impracticable to do so.
	The following table presents net sales and operating profit by reportable segment (in millions):
		IESD		CATD		Other			Total
	Three Months ended September 28, 2013:
	Net sales	$	786	$	552	$	—		$	1,338
	Operating profit	534		321		(542		)	313
	Three Months ended September 29, 2012:
	Net sales	$	792	$	534	$	—		$	1,326
	Operating profit	547		319		(631		)	235
	Nine Months ended September 28, 2013:
	Net sales	$	2,389	$	1,690	$	—		$	4,079
	Operating profit	1,630		995		(1,722		)	903
	Nine Months ended September 29, 2012:
	Net sales	$	2,482	$	1,649	$	—		$	4,131
	Operating profit	1,720		980		(1,825		)	875
	The following table presents the Company’s total assets by reportable segment (in millions):
	Total Assets	September 28, 2013		December 29, 2012
	IESD	$	2,644	$	2,320
	CATD	3,301		2,967
	Other	4,020		3,984
		$	9,965	$	9,271
	Geographic Information
	The following table presents net sales by geographic location of the customer (in millions):
		Three Months Ended				Nine Months Ended
	Net Sales	28-Sep-13		29-Sep-12		28-Sep-13			29-Sep-12
	United States	$	646	$	640	$	1,955		$	1,969
	International
	Europe	333		311		1,066			1,059
	Japan	142		172		418			500
	Asia Pacific	125		118		362			339
	Other	92		85		278			264
		692		686		2,124			2,162
		$	1,338	$	1,326	$	4,079		$	4,131
	The amounts for long-lived assets by significant geographic market include net property, plant and equipment by physical location of the asset as follows (in millions):
	Long-Lived Assets	September 28, 2013		December 29, 2012
	United States	$	1,046	$	1,036
	International
	Europe	81		82
	Japan	34		32
	Asia Pacific	77		82
	Other	189		193
		381		389
		$	1,427	$	1,425

Business_Combinations_Business1

Business Combinations Business Combinations (Tables)	9 Months Ended
	Sep. 28, 2013
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
	The preliminary allocation of the Endosense purchase price to the estimated fair values of net assets acquired was as follows (in millions):
		19-Aug-13
	Assets acquired:
	Current assets	$	2
	Goodwill	258
	Acquired in-process research and development (IPR&D)	33
	Other intangible assets	20
	Other long-term assets	1
	Total assets acquired	314
	Liabilities assumed:
	Current liabilities	11
	Net assets acquired	303
	Cash paid	180
	Cash acquired	(9		)
	Net cash consideration	171
	Contingent consideration	132
	Total purchase consideration	$	303
Spinal Modulation [Member]	'
Schedule of Variable Interest Entities [Table Text Block]	'
	The initial consolidation of a VIE that is determined to be a business is accounted for as a business combination. The following table summarizes the estimated fair values of Spinal Modulation’s assets and liabilities included in St. Jude Medical's consolidated balance sheets as of the June 7, 2013 consolidation date, and as of September 28, 2013 after elimination of all intercompany balances and transactions (in millions):
		7-Jun-13			28-Sep-13
	Cash and cash equivalents	$	41		$	31
	Other current assets	9			6
	Goodwill	82			82
	Acquired in-process research and development (IPR&D)	45			45
	Other intangible assets	7			7
	Other long-term assets	1			1
	Total assets	185			172
	Current liabilities	6			5
	Deferred income taxes, net	19			19
	Total liabilities	25			24
	Non-controlling interest	$	120		$	111
CardioMEMS, Inc. [Member]	'
Schedule of Variable Interest Entities [Table Text Block]	'
		27-Feb-13			28-Sep-13
	Cash and cash equivalents	$	33		$	21
	Other current assets	2			4
	Goodwill	83			83
	Acquired in-process research and development (IPR&D)	63			63
	Other long-term assets	2			2
	Total assets	183			173
	Current liabilities	13			6
	Deferred income taxes, net	23			23
	Other liabilities	5			4
	Total liabilities	41			33
	Non-controlling interest	$	84		$	74

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets (Tables)	9 Months Ended
	Sep. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule Of Changes In Carrying Amount Of Goodwill	'
	The changes in the carrying amount of goodwill for each of the Company’s reportable segments (see Note 14) for the nine months ended September 28, 2013 were as follows (in millions):
		IESD			CATD		Total
	Balance at December 29, 2012	$	1,229		$	1,732	$	2,961
	Endosense S.A.	—			258		258
	Spinal Modulation, Inc.	82			—		82
	CardioMEMS, Inc.	83			—		83
	Foreign currency translation and other	(12		)	11		(1		)
	Balance at September 28, 2013	$	1,382		$	2,001	$	3,383
Schedule Of Gross Carrying Amount Of Other Intangible Assets And Related Accumulated Amortization	'
	The following table provides the gross carrying amount of other intangible assets and related accumulated amortization (in millions):
		September 28, 2013					December 29, 2012
		Gross			Accumulated		Gross			Accumulated
		Carrying			Amortization		Carrying			Amortization
		Amount					Amount
	Definite-lived intangible assets:
	Purchased technology and patents	$	954		$	374	$	947		$	336
	Customer lists and relationships	22			16		57			36
	Trademarks and tradenames	22			11		22			10
	Licenses, distribution agreements and other	4			2		6			4
		$	1,002		$	403	$	1,032		$	386
	Indefinite-lived intangible assets:
	Acquired IPR&D	$	250				$	109
	Trademarks and tradenames	49					49
		$	299				$	158

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 28, 2013
Inventory, Net [Abstract]	'
Schedule Of Inventories	'
	The Company’s inventories consisted of the following (in millions):
		September 28, 2013		December 29, 2012
	Finished goods	$	475	$	416
	Work in process	59		50
	Raw materials	153		144
		$	687	$	610

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Schedule Of Long-Term Debt	'
	The Company’s debt consisted of the following (in millions):
		September 28, 2013		December 29, 2012
	2.20% senior notes due 2013 (retired September 2013)	$	—	$	454
	3.75% senior notes due 2014 (redeemed May 2013)	—		699
	2.50% senior notes due 2016	513		518
	4.875% senior notes due 2019 (redeemed May 2013)	—		496
	3.25% senior notes due 2023	896		—
	4.75% senior notes due 2043	696		—
	Term loan due 2015	500		—
	1.58% Yen-denominated senior notes due 2017	83		95
	2.04% Yen-denominated senior notes due 2020	130		149
	Yen-denominated credit facilities	66		76
	Commercial paper borrowings	585		593
	Total debt	3,469		3,080
	Less: current debt obligations	66		530
	Long-term debt	$	3,403	$	2,550

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	9 Months Ended
	Sep. 28, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule Of Product Warranty Liability	'
	Changes in the Company’s product warranty liability during the three and nine months ended September 28, 2013 and September 29, 2012 were as follows (in millions):
		Three Months Ended						Nine Months Ended
		September 28, 2013			September 29, 2012			September 28, 2013			September 29, 2012
	Balance at beginning of period	$	37		$	38		$	38		$	36
	Warranty expense recognized	(2		)	2			1			5
	Warranty credits issued	—			(1		)	(4		)	(2		)
	Balance at end of period	$	35		$	39		$	35		$	39

Special_Charges_Tables

Special Charges (Tables)	9 Months Ended
	Sep. 28, 2013
2012 Business Realignment Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Summary Of Activity Related To Special Charge Restructuring Accrual	'
	A summary of the activity related to the 2012 business realignment plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 31, 2011	$	—		$	—		$	—		$	—		$	—
	Cost of sales special charges	5			17			—			2			24
	Special charges	104			—			41			16			161
	Non-cash charges used	—			(17		)	(41		)	(3		)	(61		)
	Cash payments	(52		)	—			—			(7		)	(59		)
	Foreign exchange rate impact	1			—			—			—			1
	Balance at December 29, 2012	58			—			—			8			66
	Cost of sales special charges	—			18			—			—			18
	Special charges	10			—			2			4			16
	Non-cash charges used	—			(18		)	(2		)	—			(20		)
	Cash payments	(32		)	—			—			(3		)	(35		)
	Foreign exchange rate impact	(1		)	—			—			—			(1		)
	Balance at March 30, 2013	35			—			—			9			44
	Cost of sales special charges	—			1			—			—			1
	Special charges	19			—			2			17			38
	Non-cash charges used	—			(1		)	(2		)	(4		)	(7		)
	Cash payments	(17		)	—			—			(9		)	(26		)
	Foreign exchange rate impact	1			—			—			—			1
	Balance at June 29, 2013	38			—			—			13			51
	Cost of sales special charges	—			2			—			—			2
	Special charges	4			—			—			7			11
	Non-cash charges used	—			(2		)	—			—			(2		)
	Cash payments	(15		)	—			—			(7		)	(22		)
	Foreign exchange rate impact	—			—			—			—			—
	Balance at September 28, 2013	$	27		$	—		$	—		$	13		$	40
2011 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Summary Of Activity Related To Special Charge Restructuring Accrual	'
	A summary of the activity related to the 2011 restructuring plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 31, 2011	$	54		$	—		$	—		$	18		$	72
	Cost of sales special charges	11			13			—			20			44
	Special charges	27			—			—			31			58
	Non-cash charges used	—			(13		)	—			(4		)	(17		)
	Cash payments	(68		)	—			—			(47		)	(115		)
	Foreign exchange rate impact	1			—			—			(1		)	—
	Balance at December 29, 2012	25			—			—			17			42
	Special charges	2			—			—			7			9
	Cash payments	(13		)	—			—			(6		)	(19		)
	Balance March 30, 2013	14			—			—			18			32
	Special charges	—			—			1			3			4
	Non-cash charges used	—			—			(1		)	—			(1		)
	Cash payments	(5		)	—			—			(7		)	(12		)
	Balance at June 29, 2013	9			—			—			14			23
	Special charges	2			—			—			4			6
	Cash payments	(1		)	—			—			(5		)	(6		)
	Balance at September 28, 2013	$	10		$	—		$	—		$	13		$	23

Net_Earnings_Per_Share_Tables

Net Earnings Per Share (Tables)	9 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]	'
Schedule Of Computation Of Basic And Diluted Net Earnings Per Share	'
	The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts):
		Three Months Ended				Nine Months Ended
		September 28, 2013		September 29, 2012		September 28, 2013		September 29, 2012
	Numerator:
	Net earnings attributable to St. Jude Medical, Inc.	$	262	$	176	$	600	$	632
	Denominator:
	Basic weighted average shares outstanding	287.5		314.7		285.6		314.8
	Effect of dilutive securities:
	Employee stock options	4		1.3		2.8		1.4
	Restricted stock units	0.5		0.3		0.3		0.2
	Diluted weighted average shares outstanding	292		316.3		288.7		316.4
	Basic net earnings per share attributable to St. Jude Medical, Inc.	$	0.91	$	0.56	$	2.1	$	2.01
	Diluted net earnings per share attributable to St. Jude Medical, Inc.	$	0.9	$	0.56	$	2.08	$	2

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 28, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The tables below present the changes in each component of accumulated other comprehensive income, including other comprehensive income and reclassifications out of accumulated other comprehensive income in to net earnings for the three and nine months ended September 28, 2013 (in millions):
		Unrealized			Unrealized			Foreign			Accumulated
		gain (loss) on			gain (loss) on			Currency			Other
		available-for-sale			derivative			Translation			Comprehensive
	For the three months ended September 28, 2013	securities			instruments			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at June 29, 2013	$	18		$	3		$	(15	)	$	6
	Other comprehensive income (loss) before reclassifications	—			—			51			51
	Amounts reclassified to net earnings from accumulated other comprehensive income	(2		)	—			—			(2		)
	Other comprehensive income (loss)	(2		)	—			51			49
	Accumulated other comprehensive income (loss), net of tax, at September 28, 2013	$	16		$	3		$	36		$	55
		Unrealized			Unrealized			Foreign			Accumulated
		gain (loss) on			gain (loss) on			Currency			Other
		available-for-sale			derivative			Translation			Comprehensive
	For the nine months ended September 28, 2013	securities			instruments			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at December 29, 2012	$	20		$	—		$	26		$	46
	Other comprehensive income (loss) before reclassifications	1			3			10			14
	Amounts reclassified to net earnings from accumulated other comprehensive income	(5		)	—			—			(5		)
	Other comprehensive income (loss)	(4		)	3			10			9
	Accumulated other comprehensive income (loss), net of tax, at September 28, 2013	$	16		$	3		$	36		$	55
	The tables below present the changes in each component of accumulated other comprehensive income, including other comprehensive income and reclassifications out of accumulated other comprehensive income in to net earnings for the three and nine months ended September 29, 2012 (in millions):
		Unrealized			Foreign			Accumulated
		gain (loss) on			Currency			Other
		available-for-sale			Translation			Comprehensive
	For the three months ended September 29, 2012	securities			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at June 30, 2012	$	19		$	(48	)	$	(29	)
	Other comprehensive income (loss) before reclassifications	4			44			48
	Amounts reclassified to net earnings from accumulated other comprehensive income	(3		)	—			(3		)
	Other comprehensive income (loss)	1			44			45
	Accumulated other comprehensive income (loss), net of tax, at September 29, 2012	$	20		$	(4	)	$	16
		Unrealized			Foreign			Accumulated
		gain (loss) on			Currency			Other
		available-for-sale			Translation			Comprehensive
	For the nine months ended September 29, 2012	securities			Adjustment			Income (Loss)
	Accumulated other comprehensive income (loss), net of tax, at December 31, 2011	$	18		$	(2	)	$	16
	Other comprehensive income (loss) before reclassifications	10			(2		)	8
	Amounts reclassified to net earnings from accumulated other comprehensive income	(8		)	—			(8		)
	Other comprehensive income (loss)	2			(2		)	—
	Accumulated other comprehensive income (loss), net of tax, at September 29, 2012	$	20		$	(4	)	$	16
Schedule of Reclassifcation of Accumulated Other Comprehensive Income to Net Earnings Statement [Table Text Block]	'
	The table below provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings for the three and nine months ended September 28, 2013 and September 29, 2012 (in millions):
	Details about accumulated	Amount reclassified from accumulated other comprehensive income
	other comprehensive	Three Months Ended						Nine Months Ended
	income components	September 28, 2013			September 29, 2012			September 28, 2013			September 29, 2012			Statements of Earnings Classification
	Unrealized gain (loss) on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	4		$	5		$	9		$	14		Other expense, net
		(2		)	(2		)	(4		)	(6		)	Income tax expense
		2			3			5			8			Net earnings before noncontrolling interest
		$	2		$	3		$	5		$	8		Net earnings attributable to St. Jude Medical, Inc.

Other_Expense_Net_Tables

Other Expense, Net (Tables)	9 Months Ended
	Sep. 28, 2013
Other Nonoperating Income (Expense) [Abstract]	'
Schedule Of Other Expense, Net	'
	The Company’s other expense, net consisted of the following (in millions):
		Three Months Ended						Nine Months Ended
		September 28, 2013			September 29, 2012			September 28, 2013			September 29, 2012
	Interest income	$	(1	)	$	(1	)	$	(4	)	$	(3	)
	Interest expense	21			18			60			55
	Other	(3		)	2			192			15
	Other expense, net	$	17		$	19		$	248		$	67

Fair_Value_Measurements_And_Fi1

Fair Value Measurements And Financial Instruments (Tables)	9 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Summary Of Components Of Available-For-Sale Securities	'
	The following table summarizes the components of the balance of the Company’s available-for-sale securities at September 28, 2013 and December 29, 2012 (in millions):
		September 28, 2013				December 29, 2012
	Adjusted cost	$	7			$	9
	Gross unrealized gains	26				32
	Fair value	$	33			$	41
Summary Of Financial Assets Measured At Fair Value On A Recurring Basis	'
	A summary of financial assets measured at fair value on a recurring basis at September 28, 2013 and December 29, 2012 is as follows (in millions):
		Balance Sheet	September 28, 2013				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	848			$	848			$	—	$	—
	Available-for-sale securities	Other current assets	33				33				—		—
	Trading securities	Other assets	254				254				—		—
	Total assets		$	1,135			$	1,135			$	—	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	136			$	—			$	—	$	136
	Total liabilities		$	136			$	—			$	—	$	136
		Balance Sheet	December 29, 2012				Quoted Prices				Significant		Significant
		Classification					In Active				Other		Unobservable
							Markets				Observable		Inputs
							(Level 1)				Inputs		(Level 3)
											(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	964			$	964			$	—	$	—
	Available-for-sale securities	Other current assets	41				41				—		—
	Trading securities	Other assets	231				231				—		—
	Total assets		$	1,236			$	1,236			$	—	$	—
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
	The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs (in millions):
	Contingent Consideration Liability	Fair Value as of September 28, 2013			Valuation Technique		Unobservable Input		Range
	Endosense regulatory-based milestone	$	136		Probability Weighted Discounted Cash Flow		Discount Rate		1.15%	-	1.71%
							Probability of Payment				90%
							Projected Year of Payment				2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's contingent consideration liability associated with its Endosense acquisition subsequent to August 19, 2013 as of September 28, 2013 (in millions):
		Fiscal Year 2013
	Beginning balance	$	—
	Purchase price contingent consideration	132
	Change in fair value of contingent consideration	1
	Foreign currency translation	3
	Ending balance	$	136

Segment_And_Geographic_Informa1

Segment And Geographic Information (Tables)	9 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Schedule Of Net Sales And Operating Profit By Reportable Segment	'
	The following table presents net sales and operating profit by reportable segment (in millions):
		IESD		CATD		Other			Total
	Three Months ended September 28, 2013:
	Net sales	$	786	$	552	$	—		$	1,338
	Operating profit	534		321		(542		)	313
	Three Months ended September 29, 2012:
	Net sales	$	792	$	534	$	—		$	1,326
	Operating profit	547		319		(631		)	235
	Nine Months ended September 28, 2013:
	Net sales	$	2,389	$	1,690	$	—		$	4,079
	Operating profit	1,630		995		(1,722		)	903
	Nine Months ended September 29, 2012:
	Net sales	$	2,482	$	1,649	$	—		$	4,131
	Operating profit	1,720		980		(1,825		)	875
Schedule Of Total Assets By Reportable Segment	'
	The following table presents the Company’s total assets by reportable segment (in millions):
	Total Assets	September 28, 2013		December 29, 2012
	IESD	$	2,644	$	2,320
	CATD	3,301		2,967
	Other	4,020		3,984
		$	9,965	$	9,271
Net Sales By Geographic Location	'
	The following table presents net sales by geographic location of the customer (in millions):
		Three Months Ended				Nine Months Ended
	Net Sales	28-Sep-13		29-Sep-12		28-Sep-13			29-Sep-12
	United States	$	646	$	640	$	1,955		$	1,969
	International
	Europe	333		311		1,066			1,059
	Japan	142		172		418			500
	Asia Pacific	125		118		362			339
	Other	92		85		278			264
		692		686		2,124			2,162
		$	1,338	$	1,326	$	4,079		$	4,131
Schedule Of Long-Lived Assets By Geographic Location	'
	The amounts for long-lived assets by significant geographic market include net property, plant and equipment by physical location of the asset as follows (in millions):
	Long-Lived Assets	September 28, 2013		December 29, 2012
	United States	$	1,046	$	1,036
	International
	Europe	81		82
	Japan	34		32
	Asia Pacific	77		82
	Other	189		193
		381		389
		$	1,427	$	1,425

Basis_Of_Presentation_Basis_of

Basis Of Presentation Basis of Presentation (Narrative) (Details) (Spinal Modulation [Member], USD $)	Jun. 07, 2013
In Millions, unless otherwise specified
Spinal Modulation [Member]	'
Equity Security Ownership Interest And Allocated Value For Purchase Option	$40

Business_Combinations_Business2

Business Combinations Business Combinations (Schedule of Business Acquisitions, By Acquisition) (Details)	9 Months Ended			3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Aug. 19, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Aug. 19, 2013	Aug. 19, 2013	Aug. 19, 2013
	USD ($)	USD ($)	USD ($)	Endosense S.A. [Member]	Endosense S.A. [Member]	Endosense S.A. [Member]	Endosense S.A. [Member]	Endosense S.A. [Member]	Patented Technology [Member]
				USD ($)	CHF	USD ($)	USD ($)	In Process Research and Development [Member]	Endosense S.A. [Member]
								USD ($)	USD ($)
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business Combination, Current Assets	'	'	'	'	'	'	$2	'	'
Goodwill, Acquired During Period	'	'	'	'	'	258	'	'	'
Business Combination, Indefinite-Lived Intangible Assets	'	'	'	'	'	'	'	33	'
Business Combination, Intangible Assets, Other than Goodwill	'	'	'	'	'	'	'	'	20
Business Combination, Other Noncurrent Assets	'	'	'	'	'	'	1	'	'
Business Combination, Total Assets	'	'	'	'	'	'	314	'	'
Business Combination, Current Liabilities	'	'	'	'	'	'	11	'	'
Business Combination, Net Assets Acquired	'	'	'	'	'	'	303	'	'
Payments to Acquire Businesses, Gross	'	'	'	'	'	180	'	'	'
Cash Acquired from Acquisition	'	'	'	'	'	-9	'	'	'
Payments to Acquire Businesses, Net of Cash Acquired	171	0	'	171	160	171	'	'	'
Business Combination, Contingent Consideration, Liability	'	'	$132	'	'	'	$132	'	'

Business_Combinations_Business3

Business Combinations Business Combinations (Schedule of Variable Interest Entities) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Jun. 29, 2013

Sep. 28, 2013

Jun. 07, 2013

Sep. 28, 2013

Jun. 07, 2013

Mar. 30, 2013

Sep. 28, 2013

Feb. 27, 2013

Sep. 28, 2013

Feb. 27, 2013

Sep. 28, 2013

Jun. 07, 2013

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

Patented Technology [Member]

Patented Technology [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Variable Interest Entity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Cash and Equivalents

'

$31

$41

'

'

'

$21

$33

'

'

'

'

Business Combination, Current Assets, Other

'

6

9

'

'

'

4

2

'

'

'

'

Goodwill, Acquired During Period

82

82

'

'

'

83

83

'

'

'

'

'

Business Combination, Indefinite-Lived Intangible Assets

'

'

'

45

45

'

'

'

63

63

'

'

Business Combination, Intangible Assets, Other than Goodwill

'

'

'

'

'

'

'

'

'

'

7

7

Business Combination, Other Noncurrent Assets

'

1

1

'

'

'

2

2

'

'

'

'

Business Combination, Total Assets

'

172

185

'

'

'

173

183

'

'

'

'

Business Combination, Current Liabilities

'

5

6

'

'

'

6

13

'

'

'

'

Business Combination, Deferred Tax Liabilities Noncurrent

'

19

19

'

'

'

23

23

'

'

'

'

Business Combination, Noncurrent Liabilities, Other

'

'

'

'

'

'

4

5

'

'

'

'

Business Combination, Total Liabilities

'

24

25

'

'

'

33

41

'

'

'

'

Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value

'

$111

$120

'

'

'

$74

$84

'

'

'

'

Business_Combinations_Business4

Business Combinations Business Combinations (Narrative) (Details)

9 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2013

Sep. 29, 2012

Aug. 19, 2013

Sep. 28, 2013

Jun. 29, 2013

Jun. 07, 2013

Jun. 29, 2013

Sep. 28, 2013

Jun. 07, 2013

Sep. 28, 2013

Jun. 07, 2013

Sep. 28, 2013

Mar. 30, 2013

Feb. 27, 2013

Sep. 28, 2013

Feb. 27, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Aug. 19, 2013

Aug. 19, 2013

Sep. 28, 2013

Aug. 19, 2013

Aug. 19, 2013

Dec. 28, 2013

Oct. 11, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

USD ($)

USD ($)

USD ($)

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Endosense S.A. [Member]

Nanostim [Member]

Nanostim [Member]

Nanostim [Member]

Noncontrolling Interest [Member]

Noncontrolling Interest [Member]

USD ($)

USD ($)

USD ($)

Patented Technology [Member]

Patented Technology [Member]

Patented Technology [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

USD ($)

USD ($)

USD ($)

In Process Research and Development [Member]

In Process Research and Development [Member]

USD ($)

CHF

USD ($)

USD ($)

CHF

Patented Technology [Member]

Patented Technology [Member]

In Process Research and Development [Member]

USD ($)

USD ($)

Spinal Modulation [Member]

CardioMEMS, Inc. [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Payments to Acquire Businesses, Net of Cash Acquired

$171

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$171

160

$171

'

'

'

'

'

$118

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

165

'

165

'

150

'

'

'

'

65

'

'

'

Business Combination, Contingent Consideration, Liability

'

'

132

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

132

'

'

'

'

'

'

'

'

'

Business Combination, Net Assets Acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

303

'

'

'

'

'

'

'

'

'

Business Combination, Intangible Assets, Other than Goodwill

'

'

'

'

'

'

'

7

7

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

'

'

Business Combination, Indefinite-Lived Intangible Assets

'

'

'

'

'

'

'

'

'

45

45

'

'

'

63

63

'

'

'

'

'

'

'

33

'

'

'

'

'

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'

'

'

'

'

'12 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'

'

Equity Security Ownership Interest And Allocated Value For Purchase Option

'

'

'

'

'

40

'

'

'

'

'

'

'

60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Security Ownership Interest

'

'

'

'

'

19.00%

'

'

'

'

'

'

'

19.00%

'

'

'

'

'

'

'

'

'

'

'

18.00%

'

'

'

Additional Payment For Acquisition At Company Option

'

'

'

'

'

300

'

'

'

'

'

'

'

375

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Variable Interest Entity, Financial or Other Support, Amount

'

'

'

'

15

'

'

'

'

'

'

9

28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss

'

'

'

'

'

'

'

'

'

'

'

'

29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Purchase Accounting Adjustments

'

'

'

35

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-lived Intangible Assets, Purchase Accounting Adjustments

'

'

'

5

'

'

'

'

'

'

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Purchase Accounting Adjustments

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Liabilities, Purchase Accounting Adjustments

'

'

'

3

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$40

$5

Equity Interest, Total Ownership Percentage By All Other Investors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82.00%

'

'

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Jun. 29, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Mar. 30, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

IESD [Member]

CATD [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

Spinal Modulation [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

CardioMEMS, Inc. [Member]

Endosense [Member]

Endosense [Member]

Endosense [Member]

IESD [Member]

CATD [Member]

IESD [Member]

CATD [Member]

IESD [Member]

CATD [Member]

Goodwill [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Acquired During Period

'

'

'

$82

$82

$82

$0

$83

$83

$83

$0

$258

$0

$258

Goodwill [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at December 29, 2012

2,961

1,229

1,732

'

'

'

'

'

'

'

'

'

'

'

Foreign currency translation and other

-1

-12

11

'

'

'

'

'

'

'

'

'

'

'

Balance at September 28, 2013

$3,383

$1,382

$2,001

'

'

'

'

'

'

'

'

'

'

'

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Amount Of Other Intangible Assets And Related Accumulated Amortization) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$1,002	$1,032
Accumulated Amortization	403	386
Indefinite-lived intangible assets	299	158
Purchased Technology And Patents [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	954	947
Accumulated Amortization	374	336
Customer Lists And Relationships [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	22	57
Accumulated Amortization	16	36
Trademarks and Trade Names [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	22	22
Accumulated Amortization	11	10
Licenses, Distribution Agreements And Other [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Carrying Amount	4	6
Accumulated Amortization	2	4
In Process Research and Development [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Indefinite-lived intangible assets	250	109
Trademarks and Trade Names [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Indefinite-lived intangible assets	$49	$49

Goodwill_And_Other_Intangible_4

Goodwill And Other Intangible Assets Goodwill And Other Intangible Assets (Narrative) (Details) (Intangible Asset Charges [Member], Customer Relationships [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2013
Intangible Asset Charges [Member] | Customer Relationships [Member]	'
Impairment of Intangible Assets, Finite-lived	$13

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified
Inventory, Net [Abstract]	'	'
Finished goods	$475	$416
Work in process	59	50
Raw materials	153	144
Inventories, net	$687	$610

Debt_Schedule_Of_LongTerm_Debt

Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Debt	$3,469	$3,080
Less: current debt obligations	66	530
Long-term debt	3,403	2,550
2.20% Senior Notes Due 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	0	454
Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	0	699
Two point five percent Senior Notes Due Two Thousand Sixteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	513	518
Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	0	496
Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	896	0
Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	696	0
Term loan due 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	500	0
1.58% Yen-Denominated Senior Notes Due 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	83	95
2.04% Yen-Denominated Senior Notes Due 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	130	149
Yen Denominated Credit Facilities [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	66	76
Commercial paper borrowings [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	$585	$593

Debt_Narrative_Details

Debt (Narrative) (Details)

Sep. 28, 2013

2-May-13

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Jan. 01, 2011

Dec. 29, 2012

Jun. 30, 2012

Sep. 28, 2013

Apr. 02, 2013

Dec. 29, 2012

Sep. 28, 2013

Apr. 02, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Dec. 29, 2012

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

USD ($)

USD ($)

USD ($)

2.20% Senior Notes Due 2013 [Member]

2.20% Senior Notes Due 2013 [Member]

2.20% Senior Notes Due 2013 [Member]

Two point five percent Senior Notes Due Two Thousand Sixteen [Member]

Two point five percent Senior Notes Due Two Thousand Sixteen [Member]

Two point five percent Senior Notes Due Two Thousand Sixteen [Member]

Two point five percent Senior Notes Due Two Thousand Sixteen [Member]

Two point five percent Senior Notes Due Two Thousand Sixteen [Member]

Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]

Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]

Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]

Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]

Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]

Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]

Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]

Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]

Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]

Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]

Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]

Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]

Term loan due 2015 [Member]

Term loan due 2015 [Member]

Term loan due 2015 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

1.58% Yen-Denominated Senior Notes Due 2017 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

2.04% Yen-Denominated Senior Notes Due 2020 [Member]

Yen Denominated Credit Facilities [Member]

Yen Denominated Credit Facilities [Member]

Yen Denominated Credit Facilities [Member]

Yen Denominated Credit Facility One [Member]

Yen Denominated Credit Facility One [Member]

Yen Denominated Credit Facility Two [Member]

Yen Denominated Credit Facility Two [Member]

Credit Facility [Member]

Credit Facility [Member]

Credit Facility [Member]

Credit Facility [Member]

Commercial paper borrowings [Member]

Commercial paper borrowings [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

United States Currency Rate

USD ($)

JPY (¥)

USD ($)

JPY (¥)

USD ($)

USD ($)

JPY (¥)

USD ($)

JPY (¥)

USD ($)

USD ($)

JPY (¥)

USD ($)

Japan, Yen

Japan, Yen

Scheduled Maturity of May 2018 [Member]

Scheduled Maturity of May 2018 [Member]

Scheduled Maturity of February 2015 [Member]

United States Currency Rate

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Scheduled Maturity of May 2018 [Member]

D

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected minimum principal payments in 2014

$66,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected minimum principal payments in 2015

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected minimum principal payments in 2016

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected minimum principal payments in 2017

83,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected minimum principal payments thereafter

2,315,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

450,000,000

450,000,000

'

500,000,000

500,000,000

'

'

'

'

900,000,000

'

'

700,000,000

'

700,000,000

700,000,000

'

500,000,000

500,000,000

'

500,000,000

'

'

83,000,000

8,100,000,000

83,000,000

8,100,000,000

95,000,000

130,000,000

12,800,000,000

130,000,000

12,800,000,000

149,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Make-whole redemption charge

'

161,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument term, years

'

'

'

'

'3 years

'

'

'5 years

'

'

'

'10 years

'

'

'30 years

'

'

'5 years

'

'

'10 years

'

'

'2 years

'

'

'

'

'7 years

'7 years

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, stated percentage rate

'

'

'

2.20%

2.20%

'

2.50%

2.50%

'

'

'

'

3.25%

'

'

4.75%

'

3.75%

'

'

4.88%

'

'

'

'

'

1.58%

1.58%

1.58%

1.58%

'

2.04%

2.04%

2.04%

2.04%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, due date

'

'

'

15-Sep-13

'

'

15-Jan-16

'

'

'

'

15-Apr-23

'

'

15-Apr-43

'

'

'

'

'

'

'

'

'

'

'

28-Apr-17

28-Apr-17

'

'

'

28-Apr-20

28-Apr-20

'

'

'

'

'

'

'

'

'

'

31-May-18

'

'

'

'

'

Debt Instrument, Description of Variable Rate Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'LIBOR

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Yen LIBOR

'

'Yen LIBOR

'

'

'

'LIBOR

'

'

Debt instrument, effective interest rate

'

'

'

'

'

'

2.54%

2.54%

'

'

'

'

3.31%

'

'

4.79%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate swap term, years

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Notional Amount

'

'

'

'

'

'

500,000,000

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from termination of interest rate swap

'

'

'

'

'

'

'

'

'

'

24,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net average interest rate

'

'

'

'

'

'

'

1.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding balance under yen denominated credit facilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,000,000

6,500,000,000

76,000,000

'

'

'

'

'

'

'

'

'

'

Number of commercial banks in Japan providing financing under uncommitted credit facilities

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,250,000,000

'

'

'

'

'

'

'

'

'

'

'

Debt instrument basis spread

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.28%

'

0.25%

'

'

0.80%

'

'

'

'

Unused borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000,000

1,500,000,000

1,500,000,000

'

'

'

Maximum days commercial paper program provides for the issuance of short-term, unsecured commercial paper

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

270

'

Long-term Debt

$3,469,000,000

'

$3,080,000,000

$0

$0

$454,000,000

$513,000,000

$513,000,000

'

$518,000,000

'

$896,000,000

'

$0

$696,000,000

'

$0

$0

'

$699,000,000

$0

'

$496,000,000

$500,000,000

$0

'

$83,000,000

'

$83,000,000

'

$95,000,000

$130,000,000

'

$130,000,000

'

$149,000,000

$66,000,000

'

$76,000,000

'

'

'

'

'

'

'

'

$585,000,000

$593,000,000

Weighted average effective interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.24%

'

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details) (USD $)

Sep. 28, 2013

Sep. 28, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Jul. 15, 2013

Apr. 29, 2013

Apr. 04, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

In Millions, unless otherwise specified

VolcanoCorpvs.Lightlab [Member]

Regulatory Matters Sylmar, CA [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Riata Litigation [Member]

Silzone Litigation [Member]

Silzone Litigation [Member]

Silzone Litigation [Member]

Silzone Product Liability Insurance [Member]

D

Superior Court of California case for Los Angeles City and County [Member]

Superior Court of California case for Los Angeles City and County [Member]

Superior Court of California case for Los Angeles City and County [Member]

Superior Court of California case for Los Angeles City and County [Member]

U.S. District Court for the Central District of California [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

Federal Court [Member]

State Court [Member]

State Court [Member]

State Court [Member]

State Court [Member]

State Court [Member]

State Court [Member]

Ontario Class Action Matters [Member]

Ontario Class Action Matters [Member]

Individual Ontario Case [Member]

U.S. District Court for the District of Minnesota [Member]

U.S. District Court for the Central District of California [Member]

U.S. District Court for the District of South Carolina [Member]

U.S. District Court for the Northern District of Georgia [Member]

U.S. District Court for the Northern District of New York [Member]

U.S. District Court for the Western District of New York [Member]

U.S. District Court for the Middle District of Tennessee [Member]

U.S. District Court for the Western District of Washington [Member]

Minnesota [Member]

California [Member]

Indiana [Member]

Kentucky [Member]

Florida [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of lawsuits outstanding

'

'

'

35

'

'

'

'

'

14

3

5

1

1

1

1

1

1

21

7

10

1

2

1

'

'

'

'

Number of multi-plaintiff lawsuits outstanding, excluding class action lawsuits

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of plaintiffs to exceed in one lawsuit to result in a multi-plaintiff case

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of claimants in lawsuit

'

'

'

'

2

21

3

29

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of claimants with filed lawsuits that are not seeking suit for alleged bodily injuries from surgical removal or replacment of product

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of outstanding class actions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

Number of lawsuits outstanding, excluding class action lawsuits

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

Number of common class issues in class action suit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9

'

'

Minimum damage loss claimed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

Remaining insurance coverage for Silzone claims

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

days of legal notice

'

45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Form 483 Observations

'

'

11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_And_Contingencies_2

Commitments And Contingencies (Schedule Of Product Warranty Liability) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Balance at beginning of period	$37	$38	$38	$36
Warranty expense recognized	-2	2	1	5
Warranty credits issued	0	-1	-4	-2
Balance at end of period	$35	$39	$35	$39

Special_Charges_Summary_Of_Act

Special Charges (Summary Of Activity Related To Special Charge Restructuring Accrual) (Details) (USD $)	3 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Dec. 31, 2011	Sep. 29, 2012
2011 Restructuring Plan [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	$23	$32	$42	$72	'	'
Special charges	6	4	9	102	162	'
Non-cash charges used	'	-1	'	-17	'	'
Cash payments	-6	-12	-19	-115	'	'
Foreign exchange rate impact	'	'	'	0	'	'
Balance at ending	23	23	32	42	72	'
2011 Restructuring Plan [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	9	14	25	54	'	'
Special charges, severance and benefit costs	2	'	2	38	'	'
Non-cash charges used	'	0	'	0	'	'
Cash payments	-1	-5	-13	-68	'	'
Foreign exchange rate impact	'	'	'	1	'	'
Balance at ending	10	9	14	25	'	'
2011 Restructuring Plan [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	0	0	0	0	'	'
Non-cash charges used	'	0	'	-13	'	'
Cash payments	0	0	0	0	'	'
Foreign exchange rate impact	'	'	'	0	'	'
Balance at ending	0	0	0	0	'	'
2011 Restructuring Plan [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	0	0	'	0	'	'
Non-cash charges used	'	-1	'	0	'	'
Cash payments	0	0	'	0	'	'
Foreign exchange rate impact	'	'	'	0	'	'
Balance at ending	0	0	'	0	'	'
2011 Restructuring Plan [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	14	18	17	18	'	'
Restructuring reserve period expense	'	'	'	51	'	'
Non-cash charges used	'	0	'	-4	'	'
Cash payments	-5	-7	-6	-47	'	'
Foreign exchange rate impact	'	'	'	-1	'	'
Balance at ending	13	14	18	17	'	'
2011 Restructuring Plan [Member] | Cost of Sales [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges	'	'	'	44	'	'
2011 Restructuring Plan [Member] | Cost of Sales [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, severance and benefit costs	'	'	'	11	'	'
2011 Restructuring Plan [Member] | Cost of Sales [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, inventory obsolescence charges	'	'	'	13	'	'
2011 Restructuring Plan [Member] | Cost of Sales [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, fixed asset impairment charges	'	'	'	0	'	'
2011 Restructuring Plan [Member] | Cost of Sales [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring reserve period expense	'	'	'	20	'	'
2011 Restructuring Plan [Member] | Operating Expense [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges	6	4	9	58	'	'
2011 Restructuring Plan [Member] | Operating Expense [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, severance and benefit costs	2	0	2	27	'	'
2011 Restructuring Plan [Member] | Operating Expense [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, inventory obsolescence charges	0	0	0	0	'	'
2011 Restructuring Plan [Member] | Operating Expense [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, fixed asset impairment charges	0	1	0	0	'	'
2011 Restructuring Plan [Member] | Operating Expense [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring reserve period expense	4	3	7	31	'	'
2012 Business Realignment Restructuring Plan [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	51	44	66	0	'	'
Special charges	13	39	34	185	'	'
Non-cash charges used	-2	-7	-20	-61	'	'
Cash payments	-22	-26	-35	-59	'	'
Foreign exchange rate impact	0	1	-1	1	'	'
Balance at ending	40	51	44	66	'	'
2012 Business Realignment Restructuring Plan [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	38	35	58	0	'	'
Special charges, severance and benefit costs	4	19	10	109	'	'
Non-cash charges used	0	0	0	0	'	'
Cash payments	-15	-17	-32	-52	'	'
Foreign exchange rate impact	0	1	-1	1	'	'
Balance at ending	27	38	35	58	'	'
2012 Business Realignment Restructuring Plan [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	0	0	0	0	'	'
Non-cash charges used	-2	-1	-18	-17	'	'
Cash payments	0	0	0	0	'	'
Foreign exchange rate impact	0	0	0	0	'	'
Balance at ending	0	0	0	0	'	'
2012 Business Realignment Restructuring Plan [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	0	0	0	0	'	'
Non-cash charges used	0	-2	-2	-41	'	'
Cash payments	0	0	0	0	'	'
Foreign exchange rate impact	0	0	0	0	'	'
Balance at ending	0	0	0	0	'	'
2012 Business Realignment Restructuring Plan [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Balance at beginning	13	9	8	0	'	'
Restructuring reserve period expense	7	17	4	18	'	'
Non-cash charges used	0	-4	0	-3	'	'
Cash payments	-7	-9	-3	-7	'	'
Foreign exchange rate impact	0	0	0	0	'	'
Balance at ending	13	13	9	8	'	'
2012 Business Realignment Restructuring Plan [Member] | Cost of Sales [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges	2	1	18	24	'	'
2012 Business Realignment Restructuring Plan [Member] | Cost of Sales [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, severance and benefit costs	0	0	0	5	'	'
2012 Business Realignment Restructuring Plan [Member] | Cost of Sales [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, inventory obsolescence charges	2	1	18	17	'	'
2012 Business Realignment Restructuring Plan [Member] | Cost of Sales [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, fixed asset impairment charges	0	0	0	0	'	'
2012 Business Realignment Restructuring Plan [Member] | Cost of Sales [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring reserve period expense	0	0	0	2	'	'
2012 Business Realignment Restructuring Plan [Member] | Operating Expense [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges	11	38	16	161	'	'
2012 Business Realignment Restructuring Plan [Member] | Operating Expense [Member] | Employee Termination Costs [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, severance and benefit costs	4	19	10	104	'	'
2012 Business Realignment Restructuring Plan [Member] | Operating Expense [Member] | Inventory Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, inventory obsolescence charges	0	0	0	0	'	'
2012 Business Realignment Restructuring Plan [Member] | Operating Expense [Member] | Fixed Asset Charges [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Special charges, fixed asset impairment charges	0	2	2	41	'	'
2012 Business Realignment Restructuring Plan [Member] | Operating Expense [Member] | Other Restructuring [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring reserve period expense	$7	$17	$4	$16	'	'

Special_Charges_Narrative_Deta

Special Charges (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2012

Jun. 29, 2013

Mar. 31, 2012

Jun. 30, 2012

Sep. 29, 2012

Jun. 29, 2013

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Dec. 31, 2011

Sep. 28, 2013

Mar. 30, 2013

Dec. 29, 2012

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Dec. 29, 2012

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Mar. 30, 2013

Dec. 29, 2012

Jun. 29, 2013

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Licensing Agreements [Member]

Licensing Agreements [Member]

Intangible Asset Charges [Member]

Intangible Asset Charges [Member]

Intangible Asset Charges [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2011 Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

2012 Business Realignment Restructuring Plan [Member]

CATD [Member]

IESD [Member]

Customer Relationships [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Contract Termination [Member]

Facility Closing [Member]

Other Costs [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Contract Termination [Member]

Other Costs [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

Operating Expense [Member]

cardiac rhythm management business [Member]

cardiac rhythm management business [Member]

cardiac rhythm management business [Member]

cardiac rhythm management business [Member]

cardiac rhythm management business [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Inventory Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Fixed Asset Charges [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

CATD [Member]

CATD [Member]

CATD [Member]

IESD [Member]

Purchased In-Process Research And Development (IPR&D) And Special Charges [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Special charges

'

'

'

'

'

'

$6

$4

$9

$102

$162

'

'

'

'

'

'

'

'

'

'

'

$44

'

'

'

'

$6

$4

$9

$58

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$13

$39

$34

$185

'

'

'

'

'

'

'

'

'

'

$2

$1

$18

$24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11

$38

$16

$161

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Severance and benefit costs

'

'

'

'

'

'

'

'

'

'

'

2

2

38

'

'

'

'

'

'

'

'

'

11

'

'

'

'

'

'

'

2

0

2

27

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

19

10

109

'

'

'

'

'

'

'

'

'

'

0

0

0

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

19

10

104

'

'

'

'

'

'

'

'

'

'

'

'

Special charges, inventory obsolescence charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

1

18

17

2

18

17

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

Special charges, fixed asset impairment charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

0

1

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2

2

41

'

'

'

'

Restructuring reserve period expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51

4

3

7

37

8

'

6

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

3

7

31

'

'

'

'

'

'

'

'

7

17

4

18

7

11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7

17

4

16

Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Idle facility costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Legal settlement charge

'

22

28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets, Finite-lived

'

'

'

5

23

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchased technology and patents

$12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net_Earnings_Per_Share_Details

Net Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Net Earnings Per Share [Line Items]	'	'	'	'
Net earnings attributable to St. Jude Medical, Inc.	$262	$176	$600	$632
Basic weighted average shares outstanding	287.5	314.7	285.6	314.8
Diluted weighted average shares outstanding	292	316.3	288.7	316.4
Basic net earnings per share attributable to St. Jude Medical, Inc.	$0.91	$0.56	$2.10	$2.01
Diluted net earnings per share attributable to St. Jude Medical, Inc.	$0.90	$0.56	$2.08	$2
Common stock subject to stock options and restricted stock units excluded from the diluted net earnings per share computation	2.2	16.1	5.4	16.7
Employee Stock Options [Member]	'	'	'	'
Net Earnings Per Share [Line Items]	'	'	'	'
Effect of dilutive securities	4	1.3	2.8	1.4
Restricted Stock Units [Member]	'	'	'	'
Net Earnings Per Share [Line Items]	'	'	'	'
Effect of dilutive securities	0.5	0.3	0.3	0.2

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	$6	($29)	$46	$16
Other comprehensive income (loss) before reclassifications	51	48	14	8
Amounts reclassified to net earnings from accumulated other comprehensive income	-2	-3	-5	-8
Other comprehensive income (loss)	49	45	9	0
Accumulated other comprehensive income (loss), net of tax, Ending Balance	55	16	55	16
Unrealized gain (loss) on available-for-sale securities [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	18	19	20	18
Other comprehensive income (loss) before reclassifications	0	4	1	10
Amounts reclassified to net earnings from accumulated other comprehensive income	-2	-3	-5	-8
Other comprehensive income (loss)	-2	1	-4	2
Accumulated other comprehensive income (loss), net of tax, Ending Balance	16	20	16	20
Unrealized gain (loss) on derivative instruments [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	3	'	0	'
Other comprehensive income (loss) before reclassifications	0	'	3	'
Amounts reclassified to net earnings from accumulated other comprehensive income	0	'	0	'
Other comprehensive income (loss)	0	'	3	'
Accumulated other comprehensive income (loss), net of tax, Ending Balance	3	'	3	'
Foreign Currency Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	-15	-48	26	-2
Other comprehensive income (loss) before reclassifications	51	44	10	-2
Amounts reclassified to net earnings from accumulated other comprehensive income	0	0	0	0
Other comprehensive income (loss)	51	44	10	-2
Accumulated other comprehensive income (loss), net of tax, Ending Balance	$36	($4)	$36	($4)

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Schedule of Reclassification of Accumulated Other Comprehensive Income to Net Earnings Statement) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification adjustment from AOCI for Sale of Securities, Net of Tax	($2)	($3)	($5)	($8)
Other expense, net [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	4	5	9	14
Income tax expense [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	-2	-2	-4	-6
Net earnings before noncontrolling interest [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification adjustment from AOCI for Sale of Securities, Net of Tax	2	3	5	8
Net earnings attributable to St. Jude Medical, Inc. [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification adjustment from AOCI for Sale of Securities, Net of Tax	$2	$3	$5	$8

Other_Expense_Net_Schedule_Of_

Other Expense, Net (Schedule Of Other Expense, Net) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Other Nonoperating Income (Expense) [Abstract]	'	'	'	'
Interest income	($1)	($1)	($4)	($3)
Interest expense	21	18	60	55
Other	-3	2	192	15
Total other expense, net	$17	$19	$248	$67

Other_Expense_Net_Other_Expens

Other Expense, Net Other Expense, Net (Narrative) (Details) (USD $)	2-May-13	Mar. 30, 2013	Sep. 28, 2013	Jun. 29, 2013	Sep. 28, 2013	Jun. 29, 2013
In Millions, unless otherwise specified		CardioMEMS, Inc. [Member]	Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]	Three point seven five percent Senior Notes Due Two Thousand Fourteen [Member]	Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]	Four point eight seven five percent Senior Notes Due Two Thousand Nineteen [Member]
Debt Instrument, Face Amount	'	'	$700	$700	$500	$500
Make-whole redemption charge	161	'	'	'	'	'
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss	'	$29	'	'	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Dec. 29, 2012
Income Tax Disclosure [Abstract]	'	'
Unrecognized tax benefits	$265	$314
Accrued interest and penalties	35	69
Tax Adjustments, Settlements, and Unusual Provisions	($15)	$46

Fair_Value_Measurements_And_Fi2

Fair Value Measurements And Financial Instruments (Summary Of Components Of Available-For-Sale Securities) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]	'	'
Adjusted cost	$7	$9
Available for sale securities gross unrealized gain accumulated in AOCI	26	32
Fair value	$33	$41

Fair_Value_Measurements_And_Fi3

Fair Value Measurements And Financial Instruments (Summary of Financial Assets Measured at Fair Value, Recurring Basis) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$33,000,000	$41,000,000
Total assets	1,135,000,000	1,236,000,000
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	136,000,000	0
Liabilities, Fair Value Disclosure, Recurring	136,000,000	'
Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	1,135,000,000	1,236,000,000
Liabilities, Fair Value Disclosure, Recurring	0	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Liabilities, Fair Value Disclosure, Recurring	0	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Liabilities, Fair Value Disclosure, Recurring	136,000,000	'
Contingent Consideration Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	136,000,000	'
Contingent Consideration Liability [Member] | Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	0	'
Contingent Consideration Liability [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	0	'
Contingent Consideration Liability [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	136,000,000	'
Cash And Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money-market securities	848,000,000	964,000,000
Cash And Cash Equivalents [Member] | Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money-market securities	848,000,000	964,000,000
Cash And Cash Equivalents [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money-market securities	0	0
Cash And Cash Equivalents [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money-market securities	0	0
Other Current Assets [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	33,000,000	41,000,000
Other Current Assets [Member] | Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	33,000,000	41,000,000
Other Current Assets [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	0	0
Other Current Assets [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	0	0
Other Assets [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Trading securities	254,000,000	231,000,000
Other Assets [Member] | Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Trading securities	254,000,000	231,000,000
Other Assets [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Trading securities	0	0
Other Assets [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Trading securities	$0	$0

Fair_Value_Measurements_And_Fi4

Fair Value Measurements And Financial Instruments Fair Value Inputs, Liabilities, Quantitative Information (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013
			Significant Unobservable Inputs (Level 3) [Member]	Significant Unobservable Inputs (Level 3) [Member]	Significant Unobservable Inputs (Level 3) [Member]	Contingent Consideration Liability [Member]	Contingent Consideration Liability [Member]
				Minimum [Member]	Maximum [Member]		Significant Unobservable Inputs (Level 3) [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'	'	'	'	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value	$136,000,000	$0	'	'	'	$136,000,000	$136,000,000
Fair Value Inputs, Discount Rate	'	'	'	1.15%	1.71%	'	'
Probability of Payment	'	'	90.00%	'	'	'	'
Projected Year Of Payment	'	'	'2014	'	'	'	'

Fair_Value_Measurements_And_Fi5

Fair Value Measurements And Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (USD $)	9 Months Ended
	Sep. 28, 2013	Aug. 19, 2013
Fair Value Disclosures [Abstract]	'	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value Beginning Balance	$0	'
Business Combination, Contingent Consideration, Liability	'	132,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	1,000,000	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	3,000,000	'
Fair Value, Measurement with Unobservable Inputs, Recurring Basis, Liability Value Ending Balance	$136,000,000	'

Fair_Value_Measurements_And_Fi6

Fair Value Measurements And Financial Instruments Fair Value Measurements And Financial Instruments (Narrative) (Details) (USD $)	Sep. 28, 2013	Dec. 29, 2012	Sep. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Jun. 30, 2012	Jun. 29, 2013
In Millions, unless otherwise specified			IESD [Member]	IESD [Member]	CATD [Member]	CATD [Member]	Customer Relationships [Member]
				Intangible Asset Charges [Member]		Intangible Asset Charges [Member]	Intangible Asset Charges [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]	'	'	'	'	'	'	'
Impairment of Intangible Assets, Finite-lived	'	'	'	$23	'	$5	$13
Other Assets, Fair Value Disclosure	'	'	3	'	4	'	'
Fair Value, Estimate Not Practicable, Cost Method Investments	101	151	'	'	'	'	'
Fixed rate debt obligations fair value disclosure	2,269	'	'	'	'	'	'
Fixed rate debt obligations carrying value	2,317	'	'	'	'	'	'
Other debt carrying value	$1,152	'	'	'	'	'	'

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Details) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Apr. 02, 2013	Sep. 28, 2013	Apr. 02, 2013	Sep. 28, 2013	Jun. 30, 2012
					Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]	Three point twenty-five percent Senior Notes Due Two Thousand Twenty-three [Member]	Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]	Four point seventy-five percent Senior Notes Due Two Thousand Fourty-three [Member] [Member]	Two point five percent Senior Notes Due Two Thousand Sixteen [Member]	Two point five percent Senior Notes Due Two Thousand Sixteen [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'	'	'	'	'
The net amount of gains/(loss) recorded to other income (expense)	'	($4)	$13	$1	'	'	'	'	'	'
Proceeds from Hedge, Financing Activities	3	'	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	900	'	700	500	'
Debt instrument term, years	'	'	'	'	'10 years	'	'30 years	'	'5 years	'
Proceeds from termination of interest rate swap	'	'	'	'	'	'	'	'	'	$24
Net average interest rate	'	'	'	'	'	'	'	'	1.30%	'

Segment_And_Geographic_Informa2

Segment And Geographic Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Dec. 29, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	$1,338	$1,326	$4,079	$4,131	'
Operating profit	313	235	903	875	'
Total Assets	9,965	'	9,965	'	9,271
International, Net Sales	692	686	2,124	2,162	'
Long-Lived Assets	1,427	'	1,427	'	1,425
International, Long-Lived Assets	381	'	381	'	389
IESD [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	786	792	2,389	2,482	'
Operating profit	534	547	1,630	1,720	'
Total Assets	2,644	'	2,644	'	2,320
CATD [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	552	534	1,690	1,649	'
Operating profit	321	319	995	980	'
Total Assets	3,301	'	3,301	'	2,967
Other [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	0	0	0	0	'
Operating profit	-542	-631	-1,722	-1,825	'
Total Assets	4,020	'	4,020	'	3,984
United States [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	646	640	1,955	1,969	'
Long-Lived Assets	1,046	'	1,046	'	1,036
Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	333	311	1,066	1,059	'
Long-Lived Assets	81	'	81	'	82
Japan [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	142	172	418	500	'
Long-Lived Assets	34	'	34	'	32
Asia Pacific [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	125	118	362	339	'
Long-Lived Assets	77	'	77	'	82
Other Countries [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net sales	92	85	278	264	'
Long-Lived Assets	$189	'	$189	'	$193